Podcasts about Fadiman

Episode summary Joe and Mary dive into how platform censorship and shifting algorithms have reshaped psychedelic media, why DoubleBlind moved to a “newsletter-first” model, and what that's revealed about true audience engagement. They reflect on the post-2024 MDMA decision headwinds, state-level policy moves (wins and losses), and how funding, politics, and culture continue to reconfigure the field. They also explore alternatives to alcohol, chronic pain research, reciprocity around iboga/ibogaine, and lessons from PS25 (MAPS' Psychedelic Science 2025). Highlights & themes From platforms to inboxes: Social and search suppression (IG/FB/Google) throttled harm-reduction journalism; DoubleBlind's pivot to email dramatically improved reach and engagement. Post-MDMA decision reality: Investment cooled; Mary frames it as painful but necessary growth—an ecosystem “airing out” rather than a catastrophic pop. Policy pulse: Mixed year—some state measures stalled (e.g., MA), others advanced (e.g., NM; ongoing Colorado process). Rescheduling cannabis may add complexity more than clarity. Censorship paradox: Suppressing education makes use less safe; independent outlets need community support to keep harm-reduction info visible. Chronic pain & long COVID: Emerging overlaps and training efforts (e.g., Psychedelics & Pain communities) point beyond a psychiatry-only frame. Alcohol alternatives: Low-dose or occasional psychedelic use can shift habits for some; Mary stresses individual context and support beyond any single substance. Reciprocity & iboga: Rising interest (including from right-leaning funders) must include Indigenous consultation and fair benefit-sharing; pace of capitalism vs. community care is an active tension. PS25 field notes: Smaller, more manageable vibe than 2023; fewer “gold-rush” expectations; in-person dialogue beats online flame wars. Notable mentions DoubleBlind: Newsletter-first publishing; nurturing new writers and reported stories. Psychedelics & Pain Association / Clusterbusters: Community-driven models informing care and research (cluster headache protocols history). Books & media: Body Autonomy (Synergetic Press anthology); Joanna Kempner's work on cluster headaches - Psychedelic Outlaws; Lucy Walker's forthcoming iboga film. Compounds to watch: LSD (under-studied relative to MDMA), 2C-B, 5-MeO-DMT (synthetic focus), and broader Shulgin-inspired families.   Mary Carreon: [00:00:00] Okay, I'm gonna send it to my dad because he wants to know. Here Joe Moore: we go. Yeah, send it over. So, hi everybody. We're live Joe here with Mary Anne, how you doing today? Mary Carreon: I'm great Joe. How are you? Joe Moore: Lovely. I actually never asked you how to pronounce your last name does say it right? Mary Carreon: Yes, you did. You said it perfectly Joe Moore: lovely. Joe Moore: Um, great. So it's been a bit, um, we are streaming on LinkedIn, YouTube, Twitch X and Kick, I guess. Yeah. Kick meta. Meta doesn't let me play anymore. Um, Mary Carreon: you're in forever. Timeout. I got it. I got it. Yeah. Joe Moore: Yeah. I think they found a post the other day from 2017. They didn't like, I'm like, oh cool. Like neat, you Mary Carreon: know, you know. Mary Carreon: Yeah. That happened to me recently, actually. Uh, I had a post taken down from 2018 about, uh, mushroom gummies and yeah, it was taken down and I have strikes on my account now. So Joe Moore: Do you get the thing where they ask you if you're okay? Mary Carreon: Yes, with, but like with my searches though, [00:01:00] like if I search something or, or someone's account that has, uh, like mushroom or psychedelic or LSD or something in it, they'll be like, mm-hmm are you okay? Mary Carreon: And then it recommends getting help. So Joe Moore: it's like, to be fair, I don't know if I'm okay, but Yeah, you're like, probably not. I don't really want your help. Meta. Yeah. Mary Carreon: You're like, I actually do need help, but not from you. Thanks. Yeah, Joe Moore: yeah, yeah. Mary Carreon: So not from the techno fascists. Joe Moore: Oh, good lord. Yeah. Uh, we'll go there. Joe Moore: I'm sure. Mary Carreon: I know. I just like really dove right there. Sorry. Yeah. All right, so let's, Joe Moore: um, before we go, let's give people like a bit of, you know, high kicks on, on who is Mary, where you working these days and what are you doing? Mary Carreon: Yeah, thank you. My name is Mary Carryon and I am forever and first and foremost a journalist. Mary Carreon: I have been covering, I say the plant legalization spaces for the past decade. It's, it's been nine and a half years. Uh, on January 3rd it will be [00:02:00] 10 years. And I got my start covering cannabis, uh, at OC Weekly. And from there went to High Times, and from there went to Mary Jane, worked for Snoop Dogg. And then, uh, I am now. Mary Carreon: Double blind. And I have become recently, as of this year, the editor in chief of Double Blind, and that's where I have been currently sinking my teeth into everything. So currently, you know, at this moment I'm an editor and I am basically also a curator. So, and, and somebody who is a, uh, I guess an observer of this space more than anything these days. Mary Carreon: Um, I'm not really reporting in the same way that I was. Um, but still I am helping many journalists tell stories and, uh, I feel kind of like a story midwife in many ways. Just like helping people produce stories and get the, get the quotes, get the angles that need to be discussed, get the sentences structures right, and, um, uh, helping [00:03:00] sometimes in a visionary kind of, uh, mindset. Mary Carreon: So yeah, that's what I'm doing these days. Joe Moore: Oh, there it is. Oh, there you are. Love that. And um, you know, it's important to have, um, editors who kind of really get it from a lot of different angles. I love that we have a lot of alignment on this kind of, and the drug war thing and kind of let's, uh, hopefully start developing systems that are for people. Joe Moore: Yeah, absolutely. If you wanna just say that. Yeah, absolutely. Mary Carreon: Yeah, absolutely. Joe Moore: So, um, yeah, I almost 10 years in January. That's great. We um, it's so crazy that it's been that long. I think we just turned nine and a half, so we're maybe just a few, a few months shorter than your I love it. Plant medicine reporting career. Joe Moore: That's great. I love it. Um, yeah, so I think. I think one of the first times we chatted, [00:04:00] um, I think you were doing a piece about two cb Do you, do you have any recollection of doing a piece on two cb? Mary Carreon: I do, yes. Yes. Wait, I also remember hitting you up during an Instagram live and I was like, are you guys taking any writers? Mary Carreon: And you guys were like writers, I mean, maybe depending on the writer. Joe Moore: And I was like, I was like, I dunno how that works. Mary Carreon: Like me. Yeah. Joe Moore: Yeah. It was fun. It was fun to work with people like yourself and like get pieces out there. And eventually we had an awesome editor for a bit and that was, that was really cool to be able to like support young startup writers who have a lot of opinions and a lot of things to point out. Joe Moore: There's so much happening. Um, there was so much fraud in like wave one. Of kind of the psychedelic investment hype. There's still some, but it's lesser. Um, and it's really a fascinating space still. Like changing lives, changing not just lives, right? Like our [00:05:00] perspective towards nearly everything, right? Joe Moore: Yeah. Mary Carreon: Yes, absolutely. Absolutely. I mean, it's interesting because the space has matured. It's evolved. It's different than it was even, what a, I mean, definitely nine years ago, but even five years ago, even four years ago, even last year, things are different. The landscape is different than it was a year ago. Mary Carreon: And I, it's, it's interesting to see the politics of things. It's interesting to see who has money these days given like how hard it is just to kind of survive in this space. And it's interesting just to. Bear witness to all of this going down because it really is a once in a lifetime thing. Nothing is gonna look the same as it does now, as it, uh, then it will like in a, in a year from now or anything. Mary Carreon: So it's really, yeah. It's interesting to take account of all of this Joe Moore: That's so real. Uh, maybe a little [00:06:00] too real, like it's serious because like with everything that's going on from, um, you know, governance, governments, ai Yes. Drug policy shifts. Drug tech shifts, yes. There's so much interesting movement. Um, yes. Joe Moore: You, you know, you, you kind of called it out and I think it's really actually worth discussing here since we're both here on the air together, like this idea that the psychedelic market, not idea, the lived experience of the psychedelic market having shifted substantially. And I, I, I think there's a lot of causes. Joe Moore: But I've never had the opportunity to really chat with you about this kind of like interesting downturn in money flowing into the space. Mm-hmm. Have you thought about it? Like what might the causes be? I'm sure you have. Mary Carreon: Yeah. Yeah, I have. Yeah. I've thought about it. I mean, it's hard. Well, I don't know. I am really not trying to point fingers and that's not what I'm [00:07:00] trying to do here. Mary Carreon: But I mean, I think a lot of people were really hopeful that the FDA decision last June, not last June, the previous June, a year ago, 2024, June was going to open the floodgates in terms of funding, in terms of, um. In terms of mostly funding, but also just greater opportunities for the space and, uh, greater legitimacy granted to the psychedelic medicine space. Mary Carreon: Mm. And for those who might not know what I'm talking about, I'm talking about the, uh, FDA decision to reject, uh, MDMA assisted therapy and, um, that whole, that whole thing that happened, I'm sure if it, you didn't even have to really understand what was going on in order to get wind of that wild situation. Mary Carreon: Um, so, so maybe, yeah. You probably know what I'm talking about, but I, I do think that that had a great impact on this space. Do I think it was detrimental to this space? [00:08:00] I don't think so. We are in a growth spurt, you know, like we are growing and growing pains happen when you are evolving and changing and learning and figuring out the way forward. Mary Carreon: So I think it was kind of a natural process for all of this and. If things had gone forward like while, yeah, there probably would be more money, there would be greater opportunity in this space for people wanting to get in and get jobs and make a living and have a life for themselves in this, in this world. Mary Carreon: I don't know if it was, I don't know if it would necessarily be for the betterment of the space in general for the long term. I think that we do have to go through challenges in order for the best case scenarios to play out in the future, even though that's difficult to say now because so many of us are struggling. Mary Carreon: So, but I, but I have hope and, and that statement is coming from a place of hope for the future of this space and this culture. Joe Moore: Yeah. It's, um, I'm with [00:09:00] you. Like we have to see boom bust cycles. We have to see growth and contraction just like natural ecosystems do. Mary Carreon: Absolutely, absolutely. It has to be that way. Mary Carreon: And if it's not that way, then ifs, if. It's, it like what forms in place of that is a big bubble or like a, a hot air balloon that's inevitably going to pop, which, like, we are kind of experiencing that. But I think that the, I think that the, um, the, the air letting out of the balloon right now is a much softer experience than it would be if everything was just like a green light all the way forward, if that makes sense. Mary Carreon: So, Joe Moore: right. And there's, there's so many factors. Like I'm, I'm thinking about, uh, metas censorship like we were talking about before. Yes. Other big tech censorship, right? Mm-hmm. SEO shifts. Mary Carreon: Oh. Um, yes, absolutely. Also, uh, there were some pretty major initiatives on the state level that did not pass also this past year that really would've also kind of [00:10:00] helped the landscape a little bit. Mary Carreon: Um. In terms of creating jobs, in terms of creating opportunities for funding, in terms of having more, uh, like the perception of safer money flow into the space and that, you know, those, those things didn't happen. For instance, the measure for in Massachusetts that didn't go through and just, you know, other things that didn't happen. Mary Carreon: However, there have been really good things too, in terms of, uh, legalization or various forms of legalization, and that's in New Mexico, so we can't, you know, forget that there, and we also can't forget just the movement happening in Colorado. So there are really great things happening and the, the movement is still moving forward. Mary Carreon: Everything is still going. It's just a little more difficult than maybe it could have been Joe Moore: right. Yeah. Amen. Amen. Yes. But also, we Mary Carreon: can't forget this censorship thing. The censorship thing is a horse shit. Sorry. I'm not sure if I'm allowed to cuss, but it is, [00:11:00] but it is Joe Moore: calling it out and it's important to say this stuff. Joe Moore: And you know, folks, if you want to support independent media, please consider supporting Doubleblind and psychedelics today. From a media perspective, absolutely. We wanna wanna put as much out as we can. Yes. The more supporters we have, the more we can help all of you understand what's happening and yes. Joe Moore: Getting you to stay safer. Mary Carreon: Yeah, absolutely. And that's the whole difficulty with the censorship is that psychedelics today, and Doubleblind for instance, but also Lucid News, also other, uh, other influencers, other creators in the space, they like. What all of us are doing is putting out information that is ultimately creating a safer user experience. Mary Carreon: And so with the censorship, we are not able to do so anymore, which creates actually a lot of danger. So. Yeah, it's, it's difficult. The censorship is difficult, and if you are somebody who posts about psychedelics, I know that you know this and I am preaching to the choir. Joe Moore: Yeah. So can you talk a [00:12:00] little bit about you all at Double Blind made a major shift in the last number of months towards, uh, kind of not necessarily putting everything out there and, and kind of like, um, actually I don't even know the language you use. Joe Moore: What's the, what's the language you use for the kind of model shift you took on? Mary Carreon: Yeah, I mean, it's great. It's been a wild shift. It's been a wild shift. Um, what we are currently doing is we went to a newsletter first model, which instead of just posting onto a website for everyone to see, and then, um, you know, hopefully getting SEO hits and also posting on their, then posting those stories onto Instagram and Facebook and Twitter, and hoping to get traffic through social media. Mary Carreon: Uh, we decided that that was no longer working for us because it wasn't, um, because the censorship is so bad on, on social media, like on Instagram, for instance, and Facebook and Twitter, well, less on Twitter, [00:13:00] but still, nonetheless on social media, the censorship is so bad. And also the censorship exists on Google. Mary Carreon: When you Google search how to take mushrooms, double blinds is not even on. You know, our guide is not on the first page. It's like, you know, way the heck, way the heck down there. Maybe page 2, 3, 4, 5. I don't know. But, um, the issue, the issue with that, or, or the reason why rather that it's that way is because Google is prioritizing, um, like rehabilitation centers for this information. Mary Carreon: And also they are prioritizing, uh, medical information. So, like WebMD for instance. And all of these organizations that Google is now prioritizing are u are, are, are, are organizations that see psychedelic use through the lens of addiction or through drug drug abuse. So [00:14:00] again, you know, I don't know, take it for how you want to, I'm not gonna say, I'm not gonna tell anybody like what is the right way to use their substances or whatever. Mary Carreon: However, it's really important to have the proper harm reduction resources and tools available. Uh, just readily available, not five pages down on a Google search. So anyways, all of that said double blind was our traffic was way down. And it was looking very bleak for a while. Just we were getting kicked off of Instagram. Mary Carreon: We weren't getting any traffic from social media onto our website, onto our stories. It was a, it was a vicious kind of cycle downward, and it wasn't really working. And there was a moment there where Doubleblind almost shut down as a result of these numbers because there's a, like you, a media company cannot sustain itself on really low page views as a result. Mary Carreon: So what we [00:15:00] decided to do was go to a newsletter first model, which relies on our email list. And basically we are sending out newsletters three days a week of new original content, mostly, uh, sometimes on Wednesdays we repost an SEO story or something like that. Um, to just to engage our audience and to work with our audience that way, and to like to actually engage our audience. Mary Carreon: I cannot emphasize that enough because on Instagram and on Facebook, we were only reaching like, I don't know, not that many people, like not that many people at all. And all of that really became obvious as soon as we started sending out to our email list. And as soon as we did that, it was wild. How many, how many views to the website and also how many just open like our open rate and our click through rate were showing how our audience was reacting to our content. Mary Carreon: In other words. [00:16:00] Social media was not a good, in, like, was not a good indicator of how our content was being received at all because people kind of weren't even receiving it. So going to the newsletter first model proved to be very beneficial for us and our numbers. And also just reaching our freaking audience, which we were barely doing, I guess, on social media, which is, which is wild, you know, for, for a, an account that has a lot of followers, I forget at this exact moment, but we have a ton, double blind, has a ton of followers on, on Instagram. Mary Carreon: We were, we, we get like 500 likes or, you know, maybe like. I don't know. If you're not looking at likes and you're looking at views, like sometimes we get like 16 K views, which, you know, seems good, but also compared to the amount of followers who follow us, it's like not really that great. And we're never reaching new, like a new audience. Mary Carreon: We're always reaching the same audience too, [00:17:00] which is interesting because even with our news, with our, with our email list, we are still reaching new people, which is, which says just how much more fluid that space is. Mm-hmm. And it's because it's, because censorship does not at least yet exist in our inboxes. Mary Carreon: And so therefore email is kind of like the underground, if you will, for this kind of content and this type of material journalism, et cetera. So, so yeah. So it, it, it has been a massive shift. It is required a lot of changes over at double blind. Everything has been very intense and crazy, but it has been absolutely worth it, and it's really exciting that we're still here. Mary Carreon: I'm so grateful that Double-Blind is still around, that we are still able to tell stories and that we are still able to work with writers and nurture writers and nurture the storytelling in this space because it needs to evolve just the same way that the industry and the [00:18:00] culture and everything else is evolving. Joe Moore: Yeah, I think, I think you're spot on like the, when I watch our Instagram account, like, um, I haven't seen the number change from 107 K for two years. Mary Carreon: Absolutely. Same. And, um, same. Joe Moore: Yeah. And you know, I think, I think there's certain kinds of content that could do fine. I think, uh, psychedelic attorney, Robert Rush put up a comment, um, in response to Jack Coline's account getting taken down, um, that had some good analysis, um. Joe Moore: Of the situation. Go ahead. You had No, Mary Carreon: no, I'm just like, you know, I can't, when, when journalists are getting kicked off of these, of these platforms for their stories, for their reported stories, that's like, that is a massive red flag. And that's all I have to say. I mean, we could go into more, more details on that, but that is a [00:19:00] huge red flag. Joe Moore: Mm-hmm. Yeah. Um, for sure. The, I, yeah. And like I'm sure he'll get it back. I'm sure that's not for good, but I think he did. Okay, great. Mary Carreon: I think he did. Yeah. Yeah, I think he did. Joe Moore: Yeah. So thank you. Shout out to Jack. Yeah, thanks Jack. Um, and I think, you know, there's, there's no one with that kind of energy out there. Joe Moore: Um, and I'm excited to see what happens over time with him. Yeah. How he'll unfold. Absolutely unfold. Oh yeah. It's like, um. Crushing the beat. Mary Carreon: Oh yeah, absolutely. Especially the political, the political beat. Like, there's no, there's few people who are really tackling that specific sector, which is like mm-hmm. Mary Carreon: So exciting for a journalist. Joe Moore: Yeah. Um, so model shifting, like we all have to like, adapt in new ways. Kyle and I are still trying to figure out what we're gonna do. Like maybe it is newsletter first. Like I, I realized that I hadn't been writing for [00:20:00] years, which is problematic, um, in that like, I have a lot of things to say. Mary Carreon: Totally. Joe Moore: And nobody got to hear it. Um, so I started a substack, which I had complicated feelings about honestly. 'cause it's just another. Rich person's platform that I'm, you know, helping them get Andreessen money or whatever. And, you know, so I'm gonna play lightly there, but I will post here and there. Um, I'm just trying to figure it all out, you know, like I've put up a couple articles like this GLP one and Mushrooms article. Mary Carreon: I saw that. I saw that. Really? And honestly, that's a really, like, it's so weird, but I don't, like, it's such a weird little thing that's happening in the space. I wonder, yeah, I wonder, I wonder how that is going to evolve. It's um, you know, a lot of people, I, I briefly kind of wrote about, um, psychedelics and the GLP, is that what it is? Mary Carreon: GLP one. Joe Moore: GLP one. Say Ozempic. Yeah, just, yeah, Ozempic. Yeah, exactly. Mary Carreon: Yeah, exactly. I wrote about [00:21:00] that briefly last year and there were a bunch of people like obviously horrified, which it is kind of horrifying, but also there's a bunch of people who believe that it is extremely cutting edge, which it also is. Mary Carreon: So it's really interesting, really fascinating. Joe Moore: Yeah. Um, I remember Bernie Sanders saying like, if this drug gets as much traction as it needs to, it will bankrupt Medicaid. I guess that's not really a problem anymore. Um, but, but, uh, but so like naming it real quick, like it changed the way we had to digest things, therefore, like mushrooms get digested differently and, um, some people don't respond in the expected ways. Joe Moore: And then there was some follow up, oh, we, in the regulated model, we just do lemon tech. And then I was like, is that legal in the regulated model? And I, I don't know the answer still. Mm-hmm. Like there was a couple things, you know, if users know to do it, you know, I don't, I don't totally understand the regulated model's so strange in Oregon, Colorado, that like, we really need a couple lawyers opinions. Joe Moore: Right. I think Mary Carreon: yes, of course Joe Moore: the lawyers just gave it a [00:22:00] thumbs up. They didn't even comment on the post, which is, laughs: thanks guys. Um, Joe Moore: but you know, laughs: yeah. You're like, thank you. Joe Moore: Thanks and diversity of opinions. So yeah, there's that. And like GLP ones are so interesting in that they're, one friend reached out and said she's using it in a microdose format for chronic neuroinflammation, which I had never heard of before. Joe Moore: Whoa. And um, I think, you know, articles like that, my intent was to just say, Hey, researchers yet another thing to look at. Like, there's no end to what we need to be looking at. Abso Mary Carreon: Oh, absolutely, absolutely. You know, reporting on this space actually taught me that there's so much just in general that isn't being researched, whether that's in this space, but also beyond and how, um, yeah, just how behind, actually, maybe not, maybe behind isn't the right word, but it kind of feels from my novice and from my novice place in the, in the world and [00:23:00] understanding research, it's. Mary Carreon: Hard for me to see it as anything, but being behind in the research that we all really need, that's really going to benefit humanity. But also, you know, I get that it's because of funding and politics and whatever, whatever, you know, we can go on for days on all of that. Joe Moore: What's the real reason? What's the real reason? Joe Moore: Well, drug war. Mary Carreon: Yeah. Well, yeah, definitely the drug war. Nixon. Yeah. Yes, yes, definitely the drug war. Yeah. I mean, and just the fact that even all of the drug research that happens is, again, through the lens of addiction and drug abuse, so Joe Moore: mm-hmm. Hard to right. Yeah. Um, like ni a is obviously really ridiculous and, and the way they approach this stuff, and Carl Hart illustrates that well, and, Mary Carreon: oh man, yes, he does. Joe Moore: Like, I think Fadiman's lab in Palo Alto got shut down, like 67, 66 or 67, and like that's, you know, that was one of the later ones, Mary Carreon: right? And, Joe Moore: and like, Mary Carreon: and here we are. Joe Moore: The amount of suffering that could have been alleviated if we [00:24:00] had not done this is. Incalculable. Um, yes. Yes. Yeah. Mary Carreon: I mean the, yeah, it's hard to say exactly how specifically it would be different, but it's difficult to also not think that the fentanyl crisis and the opioid addiction rate and situation that is currently like plaguing the, the world, but particularly the United States, it's hard to think that it wouldn't be, like, it wouldn't be a different scenario altogether. Joe Moore: Right, right. Absolutely. Um, and it's, um, it's interesting to speculate about, right? Like Yeah. Yes. Where would we be? And Mary Carreon: I know, I know, I know, I know it is speculation. Absolutely. But it's like hard, as I said, it's hard not to think that things would be different. Joe Moore: Right. Right. Um, I like, there's two kind of quotes, like, um, not, this one's not really a quote. Joe Moore: Like, we haven't really had a [00:25:00] blockbuster psychiatric med since Prozac, and I think that was in the eighties or early nineties, which is terrifying. And then, um, I think this guy's name is James Hillman. He is kinda like a Jungian, um, educator and I think the title of one of his books is, we're a hundred Years Into Psychotherapy and the World is Still a Mess. Joe Moore: And I think like those two things are like, okay, so two different very white people approaches didn't go very far. Yes. Um, yes and laughs: mm-hmm. Joe Moore: Thankfully, I think a lot of people are seeing that. Mm-hmm. Um, finally and kind of putting energy into different ways. Um, Mary Carreon: yeah. Absolutely. I think, yeah, I mean, we need to be exploring the other options at this point because what is currently happening isn't working on many fronts, but including in terms of mental health especially. Mary Carreon: So mm-hmm. We gotta get going. Right? We [00:26:00] gotta get moving. Geez. Joe Moore: Have you all, have you all seen much of the information around chronic pain treatments? Like I'm, I'm a founding board member with the Psychedelics and Pain Association, which has a really fun project. Oh, that's interesting. Mary Carreon: Um, I've seen some of the studies around that and it's endlessly fascinating for obvious, for obvious reasons. Mary Carreon: I, um, we have a writer who's been working for a long time on a story, uh, about the chronic pain that has since. Become an issue for this, for her, for the writer. Mm-hmm. Um, since she had COVID. Mm-hmm. Since, since she is just like, COVID was the onset basically of this chronic pain. And, um, there she attended a psychedelics in pain, chronic pain conference and, uh, that has pretty much like, changed her world. Mary Carreon: Um, well, in terms of just the information that's out there, not necessarily that she's painless, but it's just, you know, offering a, a brand new, a brand new road, a brand new path that is giving her, [00:27:00] um, relief on days when the pain is, uh, substantial. laughs: Yeah. Mary Carreon: So that's interesting. And a lot of people are experiencing that as well. Joe Moore: Mm-hmm. So there's, there's a really cool set of overlap between the COVID researchers, long COVID researchers and the chronic pain people. 'cause there is Yes. This new science of pain that's yes. Our group, PPA put out like a really robust kind of training, um, for clinicians and researchers and even patients to get more educated. Joe Moore: And we're, we're getting, um, kind of boostered by cluster busters and we're kind of leveraging a lot of what they've done. Mary Carreon: Wait, what is a cluster buster? Joe Moore: Oh gosh. Um, so they're a 5 0 1 C3. Okay. Started with Bob Wald. Okay. Bob Wald is a cluster headache survivor. Oh, oh, oh, Mary Carreon: okay. Got it. Got it. Yes. So they're Joe Moore: the charity that, um, has been really championing, um, cluster headache research because they found a protocol [00:28:00] with mushrooms. Joe Moore: Yes, yes, yes. To eliminate. Mm-hmm. Yeah. Um, this really great, I Mary Carreon: love that. Joe Moore: This really great book was written by a Rutgers, um, I think medical sociologist or anthropologist psychedelic. Love laughs: that. Joe Moore: Joanna Kempner. Cool. Um, and it kind of talks about the whole, um, cluster busters saga, and it was, it was pretty cool. Joe Moore: Nice. So they've been at it for about as long as maps. Um, oh wow. Maybe a little earlier. Maybe a little later. Mary Carreon: I love that. Cool. I mean, yeah, that's really great. That's really great. Joe Moore: So we're copying their playbook in a lot of ways and Cool. We about to be our own 5 0 1 C3 and, um, nice. And that should be really fun. Joe Moore: And, uh, the next conference is coming up at the end of next month if people wanna check that out. Psychedelic. Nice. Mary Carreon: Nice, nice, nice. Cool. Joe Moore: Yeah, so that, like, how I leaned into that was not only did I get a lot of help from chronic pain with psychedelics and going to Phish shows and whatever, um, you know, I, and overuse for sure helped me somehow. Joe Moore: [00:29:00] Um, God bless. Yeah. But I, I like it because it breaks us out of the psychiatry only frame for psychedelics. Mm. And starts to make space for other categories. Mm-hmm. Is one of the bigger reasons I like it. Mary Carreon: Mm-hmm. Mm-hmm. Yes. Yes. Which, like, we need to be, we need to, we, no one else is gonna do it for us. We like the people in the space who are finding new uses for these substances need to be creating those, those pathways and those new niches for people to then begin studying, et cetera, and exploring and yeah. Mary Carreon: Making, making a proper avenue for, Joe Moore: right, right. And, you know, um, I don't know that this is a Maha thing, so No, I'm going there, I guess, but like, how do we kind of face squarely America and the world's drinking problems? Not [00:30:00] knowing what we know now about alcohol, you know what I mean? And then like, what are the alternatives? Joe Moore: You know, some, some writers out there on substack are very firm that everybody needs to not do any substance. And like all psychedelics are super bad and drugs are evil, you know, famous sub stackers that I won't name. But you know, like what is the alternative? Like, I, like we have to have something beyond alcohol. Joe Moore: And I think you've found some cannabis helpful for that. Mary Carreon: Yeah, I, you know, it's, it's interesting because it's, there are, there's definitely an argument to be made for the power of these substances in helping, I don't wanna, I don't wanna say curb, but definitely reduce the symptoms of, uh, wanting to use or to drink or to consume a specific substance. Mary Carreon: There's obviously there is an argument to be made. There are, there is ano another camp of people who are kind [00:31:00] of in the, in the, in the, in the realm of using a drug to get off of a drug isn't how you do it. However, and, and I do, it depends on the individual. It depends on the individual and the, and how that person is engaging with their own addiction. Mary Carreon: I think for whether or not the substances work, like whether psychedelics work to help somebody kind of get off of alcohol or get off of cocaine or stop using opioids or, you know, et cetera. Mm-hmm. However, I think like, when the situation is so dire, we need to be trying everything. And if that means, like, if, like, you know, if you look at the studies for like smoking cessation or alcohol use, mushrooms do help, psilocybin does help with that. Mary Carreon: Mm-hmm. But, you know, there's, there's a lot of, there's a lot of things that also need to happen. There's a lot of things that also need to happen in order for those, uh, that relief to maintain and to stick and to, uh, really guide [00:32:00] somebody off of those substances. Mm-hmm. It's not just the substance itself. Joe Moore: Right. So I'm, I'm explicitly talking like recreational alternatives, right. Like how do I Yeah. On per minute, like, am Anitas becoming helpful? Yeah, yeah. Are helpful and Yeah. Yeah. I think like even, um, normal. What we might call like normal American alcohol use. Like Yeah. That's still like, quite carcinogenic and like, um, absolutely. Joe Moore: We're kind of trying to spend less as a country on cancer treatments, which I hope is true. Then how do we, how do we develop things that are, you know, not just abstinence only programs, which we know for sure aren't great. Mary Carreon: Yeah. They don't work. Yeah. I don't, it's, it's difficult. Mm-hmm. It's difficult to say. Mary Carreon: I mean mm-hmm. I don't know. Obviously I, I, well, maybe it's not obvious at all for people who don't know me, but, you know, I exist in a, I exist in, in a world where recreational use is like, it's like hard to define what recreational use is because if we are using this, if we are using mushrooms or LSD even, or MDMA, [00:33:00] you know, there are so many, there's a lot of the therapy that can happen through the use of these substances, even if we're not doing it, you know, with a blindfold on or whatever and yeah, I think like. Mary Carreon: There is a decent swap that can happen if you, if you are somebody who doesn't wanna be, you know, having like three beers a night, or if you are somebody who's like, you know, maybe not trying to have like a bottle of wine at a night or something like that, you know, because like Americans drink a lot and a lot of the way that we drink is, um, you know, like we don't see it as alcoholism. Mary Carreon: Even though it could be, it could be that's like a difficult Joe Moore: potentially subclinical, but right there. Mary Carreon: Um, yeah. Yeah. It's like, you know, it's, um, we don't see it as that because everybody, a lot of people, not everybody, but a lot of people drink like that, if that makes sense. If you know mm-hmm. If you, if you get what I'm, if you get what I'm saying. Mary Carreon: So, you know, I do think that there's a lot of benefit that, I don't [00:34:00] know, having, like a, having a mushroom, having a mushroom experience can really help. Or sometimes even like low dose, low doses of mushrooms can also really help with, like, with the. Desire to reach for a drink. Yeah, totally. And, and AMS as well. Mary Carreon: I know that that's also helping people a lot too. And again, outside of the clinical framework. Joe Moore: Yeah. I'm, a lot of people project on me that I'm just like constantly doing everything all the time and I'm, I'm the most sober I've been since high school. You know, like it's bonkers that like Yeah. Um, and you know, probably the healthiest event since high school too. Joe Moore: Yeah. But it's fa it's fascinating that like, you know, psychedelics kind of helped get here and even if it was like For sure something that didn't look like therapy. Yeah, Mary Carreon: yeah, yeah, yeah. Absolutely. Absolutely. Yeah. I, I think, I think most of us here in this space are getting projected on as to like, you know, being like what Normies would consider druggies or something, or that we are just like, you know, high all the time. Mary Carreon: Um, [00:35:00] I know that that is definitely something that I face regularly, like out in the world. Um, but, you know, I would also, I would also argue that. Uh, like mushrooms have completely altered my approach to health, my approach to mental health, and not even having to consume that, you know, that substance in order or that, you know, that fun fungi, in order for me to like tap into taking care of my mental health or approaching better, uh, food options, et cetera. Mary Carreon: It's kind of like what these, it's like how the mushrooms continue to help you even after you have taken them. Like the messages still keep coming through if you work with them in that capacity. Right. And yeah, and also same with, same with LSD too. LSD has also kind my experiences with that have also guided me towards a healthier path as well. Mary Carreon: I, I understand that maybe for some people it's not that way, but, um, for me that substance is a medicine as well, [00:36:00] or it can be. Joe Moore: Yeah. Um, so. What are, what are some things popping up these days about like US drug policy that's like getting exciting for you? Like, are you feeling feeling like a looming optimism about a, a major shift? Joe Moore: Are you kind of like cautiously optimistic with some of the weird kind of mandatory minimum stuff that's coming up or? Mary Carreon: Yeah. Yeah. I mean, I know that there was a huge, a, a pretty huge shift over at the DEA and I wish I remembered, I wish I remembered his name. The new guy who's now, I believe the head of the DEA, I don't know enough information about it to really feel a way. Mary Carreon: However, I don't think that he's necessarily going to be serving us as a community here, uh, in the psychedelic space. I, you know, I just don't think that that's something that we can ever depend on with the DEA. Uh, I also don't think that [00:37:00] the DEA is necessarily going to be. All that helpful to cannabis, like the cannabis space either. Mary Carreon: Um, I know that, that Trump keeps kind of discussing or, or dangling a carrot around the rescheduling of cannabis. Um, for, he's been, he's been, but he's doing it a lot more now. He's been talking about it more recently. Uh, he says like, in the next like couple weeks that he's going to have some kind of decision around that, allegedly. Mary Carreon: But we will see also, I'm not sure that it's going to necessarily help anybody if we reschedule two. Uh, what from schedule one to schedule th two, three, schedule three. Joe Moore: Either way it's like not that useful. Right. Exactly. Mary Carreon: Yeah. Yeah, exactly. It's, um, just going to probably cause a lot more red tape and a lot of confusion for the state rec markets. Mary Carreon: So it's like something that we, it's like only ridden with unintentional, unintentional consequences. Unintended consequences. Mm-hmm. Because no one knows how it's really going to [00:38:00] impact anything, um, if, if at all. But I don't know. It's hard, it's hard to imagine that there won't be any, uh, like more complex regulatory issues for business owners and also probably consumers as well. Joe Moore: Hmm. Yeah. This guy's name's Terry Cole. Mary Carreon: Oh, the new DEA guy. Joe Moore: Yeah. Um, I don't know much about him. Terry. Yeah. Terry, I would love to chat. Mary Carreon: Yeah. Terry, let's talk. I'm sure your people Joe Moore: are watching. Yeah. So like, just let him know. We wanna chat. Yeah. We'll come to DC and chat it out. Um, yeah. It's, um, but yeah, I, Carl Hart's solution to me makes like almost most of the sense in the world to just end the scheduling system Absolutely. Joe Moore: And start building some sort of infrastructure to keep people safe. That's clearly not what we have today. Mary Carreon: No. But building an infrastructure around the health and wellness and uh, safety of [00:39:00] people is the exact opposite system that we have currently right now. Because also the scheduling system has a lot to do with the incarceration in the United States and the criminal just, or the criminal system. Mary Carreon: So, so yeah, like we can't disentangle the two really. Joe Moore: It just started, um, I feel negligent on this. Uh, synergetic press put out a book like a year or two ago called Body Autonomy. Mm-hmm. Um, did that one come across your desk at all? Mm-hmm. No. I wish basically contributed. Oh, nice. A number of people. So it's both like, um. Joe Moore: Drug policy commentary and then like sex work commentary. Oh, nice. And it was like high level, like love that really, really incredible love that detailed science based conversations, which is not what we have around this. Like, that doesn't make me feel good. So you should go to jail kind of stuff. Or like, I'm gonna humiliate you for real though. Joe Moore: Ticket. Yeah, Mary Carreon: yeah, yeah, yeah, yeah. Oh God. Uh, when you think about it like that, it just really also shows [00:40:00] just the uh, um, the level at which religion has also kind of fundamentally infused itself into the scheduling system, but also our laws, you know, like what you just said, this like, shame-based, I'm going to embarrass you and make you into a criminal when you know actually you are a law for the most part, a law abiding citizen, with the exception of this one thing that you're doing for. Mary Carreon: A, your survival and or your, like, your feeling good, wanting to feel good addressing pain. Um, there's a large, uh, like noise coming out of the front yard of my house right now. Hold on. Just a, it doesn't sound too bad. It doesn't sound too bad. Okay. Okay, good. Not at all. Not at all. Okay. Yeah, I had Joe Moore: people working on my roof all day and somehow it worked out. Joe Moore: Oh, good. Um, yeah. Um, yeah, it's, it's fascinating and I, I've been coming around like, I, I identify as politically confused, [00:41:00] um, and I feel like it's the most honest way I can be. Um, Mary Carreon: I am also politically confused these days, impossible to align with any, uh, party or group currently in existence at this exact juncture in American history. Joe Moore: I can't find any that I want to throw my dice in with. Nah. This idea of like fucking way being. Like what is the most humane way to do government as a way it's been put to me recently. And that's interesting. So it comes down to like coercion, are we caring for people, things like that. And um, I don't think we're doing it in a super humane way right now. Mary Carreon: Um, we, yeah, I am pretty sure that even if there was, I mean, I think that even if we looked at the data, the data would support that we are not doing it in a humane way. Joe Moore: So Mary Carreon: unfortunately, and Joe Moore: you know, this whole tech thing, like the tech oligarch thing, you kind of dropped at the beginning and I think it's worth bringing that back because we're, we're on all [00:42:00] these tech platforms. Joe Moore: Like that's kind of like how we're transmitting it to people who are participating in these other platforms and like, you know, it's not all meta. I did turn on my personal Facebook, so everybody's watching it there. I hope. Um, see if that count gets, Mary Carreon: um, Joe Moore: but you know, this idea that a certain number of private corporations kind of control. Joe Moore: A huge portion of rhetoric. Um, and you know, I think we probably got Whiffs of this when Bezos bought Washington Post and then Yes. You know, Musk with X and like yes. You know, is this kind of a bunch of people who don't necessarily care about this topic and the way we do, and they're like in larger topics too about humane government and like, you know, moving things in good directions. Joe Moore: Um, I don't know, thoughts on that rift there as it relates to anything you, wherever you wanna go. Yeah. Mary Carreon: Yeah. I mean, I don't think that they are looking at, I don't think that they are looking [00:43:00] at it the way that we are. I don't think that they can see it from their vantage point. Um, I think that like, in the, in a similar way that so many CEOs who run businesses have no fucking clue about what's actually happening in their businesses and the actual workers and, and employees of their businesses can tell them in more detail. Mary Carreon: Far more detail about what's actually happening on the, on the floor of their own business. Uh, I think that it is something like that. However, that's not to say that, you know, these, these CEOs who employ people who build the A algorithm are obviously guided to create the limitations on us as people who speak about drugs, et cetera, and are creating a algorithm that ultimately is looking at things in a very blanket way in terms of, uh, like we're probably seen on the same level as like drug dealers, if that makes sense. Mary Carreon: Which is obviously a much, you know, there's, [00:44:00] it's a very different thing. Um, so, you know, there's like these CEOs are giving directions to their employees to ultimately create systems that harm. Information flow and inform and, and like the information health of, of platforms and of just people in general. Mary Carreon: So it's hard to say because there's nuance there, obviously, but I would bet you that someone like Elon Musk doesn't really have a full grasp as to the, the nuances and details of what's even happening within, on the ground floor of his businesses. Because that's like, not how CEOs in America run, run, and operate. Mary Carreon: They're stupid companies. So, so yeah. And I feel like that, like, that's across the board, like that's across the board. That's how I, that's probably how Zuck is operating with Meta and Facebook, et cetera. And yeah, just likewise and across, across the whole, [00:45:00] across the whole spectrum. Joe Moore: Mm-hmm. Yeah. And I think, um, a thing. Joe Moore: Then as the people like, we need to keep looking at how can we keep each other informed. And that's kind of circling back to drug journalism like we do and like, um, other, other sorts of journalism that doesn't really get the press it deserves. Right. And I've been getting far more content that I find more valuable off of tragically back on Zucks platform like IG is getting me so much interesting content from around the world that no major outlet's covering. Mary Carreon: That's so interesting. Like what? Like what would you say? Joe Moore: Oh, um, uh, certain, um, violent situations overseas. Oh, oh, got it. Yeah, yeah, yeah. And, um, you know, that America's paying for, so like, you know, I just don't love that I don't have a good, you know, journalistic source I can [00:46:00] point to, to say, hey, like right. Joe Moore: These writers with names, with addresses, like, and offices here. Yes. You know, they did the work and they're held, you know, they're ethical journalists, so yes. You can trust them. Right. You know what I mean? Yes, Mary Carreon: yes. Yeah, yeah, yeah. I mean, all of this makes everything so much harder for determining, like, the censorship specifically makes it so much harder for the people to determine like, what's real, what's not. Mary Carreon: Because, because of exactly what you just said. Mm-hmm. Like, you know, we are, we are basically what that means, like what is required of the people and people who are consuming information is becoming a smart consumer and being able to determine what's real, what's not. How can we trust this individual? Mary Carreon: How can we not, which isn't analysis process that all of us need to be sharpening every single day, especially with the advent of AI and, uh, how quickly this, this type of content is coming at all of us. Like, especially if you're on TikTok, which many of us are, you know, like information comes flying at you 3000 miles an hour, and it's sometimes [00:47:00] really difficult to determine what's real, what's not, because AI is. Mary Carreon: AI is not where it's going to be, and it still is in its nascent phase. However, it's still pretty fucking good and it's still very confusing on there. So, so again, like the media literacy of the people needs to be sharpened every single day. We cannot be on there, we cannot be on the internet existing. Mary Carreon: That everything that we are seeing is real. Whether that's about, you know, these, um, the violence overseas, uh, happening at the hands of the United States, whether that is, uh, even drug information like, you know, et cetera, all of all of it. Or just like news about something happening at Yellowstone National Park or something that is happening in the, uh, at like. Mary Carreon: Um, like potential riots also happening at protests in downtown la, et cetera. Like all, all of it, we need to be so careful. And I think what that also, like, one way that [00:48:00] we can adjust and begin to develop our media literacy skills is talking to people maybe who are there, reaching out to people who are saying that they were there and asking them questions, and also sussing that out. Mary Carreon: You know, obviously we can't do that for all situations, but definitely some of them. Joe Moore: Yeah, absolutely. Like, Joe Moore: um, a quick pivot. Mm-hmm. Were you at PS 25? Mary Carreon: Yes, I was. What did I think? Uh, you know, I, I was running around like crazy at this one. I felt like I didn't even have a second to breathe and I feel like I didn't even have a second to really see anybody. I was like, worry. I was jumping from one stage to the next. Mary Carreon: However, I would say, uh, one of, one of the things that I have said and how I felt about it was that I felt that this, this event was smaller than it was two years ago. And I preferred that I preferred the reduction in size just because it was, uh, less over, less overwhelming [00:49:00] in an, in an already very overwhelming event. Mary Carreon: Um, but I thought that from the panels that I did see that everyone did a really great job. I thought that maps, you know, it's impressive that maps can put on an event like that. Um, I also was very cognizant that the suits were there in full effect and, uh, you know, but that's not unusual. That's how it was last time as well. Mary Carreon: And, um, I felt that there was Mary Carreon: a, uh, like the, the, the level of excitement and the level of like opportunity and pro, like the prosperous. The like, prospect of prosperity coming down the pipeline like tomorrow, you know, kind of vibe was different than last time. Mm-hmm. Which that was very present at the one, two years ago, uh, which was the last PS psychedelic science. Mary Carreon: Yeah. Um, anyways. Yeah. But it was, you know, it was really nice to see everybody. [00:50:00] I feel like in-person events is a great way for everybody in the psychedelic space to be interacting with each other instead of like keyboard warrioring against each other, you know, uh, over the computer and over the internet. Mary Carreon: I think that, um, yeah, uh, being in person is better than being fighting each other over the internet, so, yeah. Joe Moore: Mm-hmm. People seem to be a little bit more civil in person. Mary Carreon: Exactly. Exactly. Mm-hmm. And I think that that is something that we all need to be considering more often, and also inviting people from across the aisle to your events and creating peace, because in person it's a little different than it is. Mary Carreon: When you have the opportunity to, uh, yeah, like keyboard attack someone over the internet, it's like, yeah. It's just so silly. So silly. We look like fools. Like we look like absolute idiots doing that. And you know what? I cannot sit here and say that I haven't looked like an idiot. So, you know, it's like I'm not, I'm not talking from like a high horse over here, but, but you know, it's like, it's [00:51:00] better when it's in person. Mary Carreon: I feel like there's like more civil engagements that we can all have. Joe Moore: It's practice, you know? Yeah. We're learning. Yeah. We are. We should be learning, including us, and yes, of course. Um, I, I play a subtler game these days and, uh, you know, I, I, I, it's better when we all look a lot better in my opinion, because yes, we can inform policy decisions, we can be the ones helping inform really important things about how these things should get implemented and absolutely right. Joe Moore: Like, Mary Carreon: absolutely. Yeah, it does. It does. Nobody, any service, especially these medicines, especially these sacraments, especially these plants, these molecules, et cetera, if we are all sitting here fighting each other and like calling each other names and trying to dunk on one another, when like in reality, we are also all kind of pushing for the same thing more or less. Joe Moore: Mm-hmm. So a thing that [00:52:00] I, it's a, it's kind of a, I, I had a great time at PS 25. I have no, no real complaints. I just wish I had more time. Yeah, same. Um, same. Yeah. Our booth was so busy. It was so fun. Just good. And it was like, good. I, I know. It was really good. I'm trying to say it out loud. I get to talk at the conference before Rick did. laughs: Oh, oh, Joe Moore: the morning show they put us on at like seven 30 in the morning or something crazy. Oh my god. It was early. I dunno if it was seven 30. Mary Carreon: That's so early. That's so early. Joe Moore: Yeah, right. Like that's crazy. I got zero nightlife in That's okay. Um, I was not, I was there for work. Yeah, Mary Carreon: yeah. I was Joe Moore: jealous. I didn't party, but you know, whatever. Joe Moore: Yeah, yeah. Mary Carreon: I did not party this time really in the same way that I did at PS 20. Was it 2023? Joe Moore: 23, yeah. 23. I only stay up till 11 one night in 23. Nice. Mary Carreon: Okay. Um, okay. Joe Moore: So I behaved, I have a pattern of behaving. 'cause I like That's good. I'm so bent outta shape inside going into these things. I'm like, I know, I know. Joe Moore: And, and I'm like, oh, all [00:53:00] my friends are gonna be there. It's gonna be great. And then it's like, yeah. It's mostly friends and only a little bit of stress. Yeah. Um, yeah. Yeah, Mary Carreon: yeah. I had a, I had a great time. It was really good seeing everybody again. Like you, I wish that I had more time with people. Like there are people that I like didn't even see who are my friends, Joe Moore: so, which Yeah. Joe Moore: Which is sad. That's like a subtext in, in like the notes coming away from 25. Is that the, um, American Right, if we wanna call it that, is very interested in this stuff. Oh yeah. Like the Texas establishment. Oh yeah. Um, the Texas contingent, right? They're deep. They're real deep. Mm-hmm. I have, um, Mary Carreon: let's talk about that more. Mary Carreon: Yeah. So Joe Moore: it's optimistic in, in some sense that psychedelic science is getting funded more. By states. 'cause the feds aren't stepping up. Right. I love that. Right. Yeah. Like, Hey feds, look what we can do. And you can't somehow, and [00:54:00] then, um, we'll see if state rights stays around for a while longer, maybe, maybe not. Joe Moore: And then the other part is like, is there a slippery slope given the rhetoric around addiction and the rise in interest in iboga for compulsory addiction treatment with psychedelics or, or compulsory mental health treatments with psychedelics because of the recent, it's illegal to be a person without housing. Joe Moore: Um, and you're gonna get put in treatment. Mm. Like, that's now a thing. So like, I don't know, I don't think forced treatment's good at all. I, and I don't think like, um, like the data is something like 15% effective, maybe less. Right. Right. It's not a good use of money. I don't know. We're, let's, I. You can go there if you want, and riff on that, or if you wanna talk about like, Texas, um, Arizona more generally. Mary Carreon: Yeah. I mean, I will just say this, I also don't really believe that forced treatment is like good, you [00:55:00] know, data Joe Moore: says it's bad. Mary Carreon: Yeah. Yeah. I also, yeah, I mean, it's like, I don't know. Yeah, that's, it's complex. It's a complex issue. I also don't think it's good, but I also do think that we need a much better framework and foundation for like, if people do want the help, helping them get it. Mary Carreon: Much more easily and in a way that's going to be beneficial for them. Um, and I don't think that that system or that pathway currently exists as we saw in, uh, with, with, um, measure 1 0 9 and the failure of measure 1 0 9 or, or was it Measure 1 0 10, 1 10, measure one 10 in Oregon. Joe Moore: But did you see the response yesterday or two days ago? Joe Moore: No, I didn't. No, I didn't. I'll I'll send it to you later. Okay. So the university did the research, um, Portland State University did the research Yes. And said, Hey, look, there was actually 20 other things that were higher priority. Like that actually influenced this increase in overdoses, not our law. Mary Carreon: Right. Mary Carreon: Yes. It was really COVID for Okay. [00:56:00] Like for, yeah. Right. Absolutely. Also, there was not a. Like there was not a framework in place that allowed people to get off the street should they want to, or you know, like, like you just can't really have a, all drugs are legal, or small amounts of drugs are legal without also offering or creating a structure for people to get help. Mary Carreon: That, that's, you can't do one without the other. Unfortunately. That's just like a, that's faulty from the start. So that's all I'll really say about that. And I don't think that that had fully been implemented yet, even though it was something that wasn't ideal for the, um, for the, for the measure. And I believe it was measure one 10, not measure 1 0 9, to be clear. Mary Carreon: Measure one 10. Um, yes, but confirmed one 10 confirmed one 10, yes. Mm-hmm. Um, but yeah, uh, that's, you know, that's kind of what I'll say. That's what I'll, that's where I'll leave that portion. Mm-hmm. You know? Uh, but yeah, forced treatment. I don't know. [00:57:00] We can't be forcing, forcing people to do stuff like that. Mary Carreon: I don't know. It's not gonna, it's, yeah, it doesn't seem Joe Moore: very humane. Mary Carreon: Yeah. No. And it also probably isn't gonna work, so, Joe Moore: right. Like, if we're being conservative with money, like, I like tote, like to put on Republican boots once in a while and say like, what does this feel like? And then say like, okay, if we're trying to spend money smartly, like where do we actually get where we want to be? Joe Moore: And then sometimes I put on my cross and I'm like, okay, if I'm trying to be Christian, like where is the most, like, what is the most Christian behavior here in terms of like, what would the, you know, buddy Jesus want to do? And I'm just like, okay, cool. Like, that doesn't seem right. Like those things don't seem to align. Joe Moore: And when we can find like compassionate and efficient things, like isn't that the path? Um, Mary Carreon: compassionate and t. Yeah, even, I don't know, I don't know if it looks lefty these days, but Yeah, I know what you mean. Yeah, I know what you mean. I know what you mean. Yeah. [00:58:00] Yeah. Um, yeah, it's complicated. It's complicated, you know, but going back, kind of, kind of pivoting and going back to what you were talking about in regards to the subtext, some of the subtext of like, you know, where psychedelic medicine is currently getting its most funding. Mary Carreon: You know, I do believe that that was an undercurrent at psychedelic science. It was the, the iboga conversation. And there's, there's a lot, there's a lot happening with the Iboga conversation and the Iboga conversation and, um, I am really trying to be open to listening to everyone's messages that are currently involved in. Mary Carreon: That rise of that medicine right now? Um, obviously, yeah, we will see, we'll see how it goes. There's obviously a lot of people who believe that this is not the right move, uh, just because there's been no discussions with, uh, the Wii people of West Africa and, you know, because of [00:59:00] that, like we are not talking to the indigenous people about how we are using their medicine, um, or medicine that does like that comes from, that comes from Africa. Mary Carreon: Um, also with that, I know that there is a massive just devastating opioid crisis here that we need to do something about and drug crisis that we need to be helping with. And this medicine is something that can really, really, really help. Um, I find it absolutely fascinating that the right is the most interested party in moving all of this forward, like psychedelic medicine forward. Mary Carreon: And I, I currently have my popcorn and I am watching and I am eating it, and I am going to witness whatever goes down. Um, but I'm, I, I hope that, uh, things are moving in a way that is going to be beneficial for the people and also not completely leave behind the indigenous communities where this medicine comes from. Joe Moore: [01:00:00] Mm-hmm. Mary Carreon: We'll see how it goes. Yeah. We'll see how it goes. We'll see how it goes. It Joe Moore: would be lovely if we can figure it out. Um, I know, and I think, uh, Lucy Walker has a film coming out on Iboga. Mm. I got to see it at Aspen, um, symposium last summer, and it was really good. Mm. So I'm sure it'll be cut different, but it's so good and it tells that story. Joe Moore: Okay. Um, in a helpful way. I'm gonna, I, yeah. I always say I'm gonna do this. I'm like, if I have space, maybe I'll be able to email her and see if we can screen it in Colorado. But it's like a brilliant film. Yeah. Cool. This whole reciprocity conversation is interesting and challenging. And so challenging being one of the few countries that did not sign onto the Nagoya protocol. Joe Moore: Absolutely. We're not legally bound, you know, some countries are Mary Carreon: I know. Yes, yes, yes. So Joe Moore: we're, you know, how do we do that? How do we do that skillfully? We still haven't done it with, um, first Nations folks around their [01:01:00] substances. Um, I think mushrooms are a little flexible and account of them being global, um, from Africa to Ireland and beyond. Joe Moore: And, but you know, that's, we still want to give a nod to the people in Mexico for sure. Yeah, absolutely. Absolutely. Yeah. Um, yeah. Yeah, it's, I had some fun commentary there that I would love to flesh out someday. Uh, but yeah, it's not for today. Mary Carreon: Yeah, yeah, yeah. Um, there's, yeah, there's obviously, there's obviously a lot with the conversation of reciprocity here and, um, I know, I, I don't know. Mary Carreon: I, I, what I do know is that we need to be listening to the indigenous people, not just listening to them second, like secondhand or listening to them, uh, once we have moved something forward, like actually consulting with them as the process goes. And that, you know, the way that both parties move, indigenous folks and, uh, western folks move, uh, are at inherently different paces. Mary Carreon: And, [01:02:00] um, I just hope, and I wish, and I, I hope, I just hope that, uh, Western what, like the Western party, the western folks who are diving into these medicines. Slow the fuck down and listen and just are able to at least make one right move. Just one, just like you. Like it's, doesn't have to be this, it doesn't have to be that hard. Mary Carreon: Although the pace of capitalism usually propels, uh, the western folks at, at a much quicker rate than, u

Jim talks with James Fadiman and Jordan Gruber about the findings in their recent book Microdosing for Health, Healing, and Enhanced Performance. They discuss the definition of microdosing, "subthreshold" vs "subperceptual," typical doses, current usage statistics & demographics, its legal status & classification history, LSD, psilocybin, why cannabis isn't suitable for microdosing, mechanisms of action, dosing protocols, anti-inflammatory effects, health applications, enhancement applications, contraindications & side effects, research methodologies & limitations, commercial potential, global adoption patterns, and much more. Episode Transcript Microdosing for Health, Healing, and Enhanced Performance, by James Fadiman and Jordan Gruber The Psychedelic Explorer's Guide, by James Fadiman Your Symphony of Selves, by James Fadiman and Jordan Gruber JRS EP126 - Jordan Gruber & James Fadiman on Our Symphony of Selves Autism on Acid, by Aaron Paul Orsini Institute of Noetic Sciences James Fadiman, Ph.D., is a prominent figure in the field of psychedelic research, particularly known for his work on microdosing psychedelics like LSD and psilocybin. Often called the “father of microdosing,” Fadiman has a long history in the study of psychedelics dating back to the 1960s, when he worked on studies involving LSD and creativity while at Stanford University. After psychedelics were banned in the U.S., Fadiman shifted his focus but returned to psychedelic research decades later. His book, The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys, has become a key resource for safe psychedelic exploration. In recent years, he has pioneered research on microdosing, examining its potential benefits for mental health, cognitive enhancement, and overall well-being. Jordan Gruber, JD, MA, founded the early online Enlightenment.Com community. After practicing law at Cooley Godward and focusing on IP law at NASA's Moffett Field, as well as working at GNOSIS Magazine, Jordan became “the Practical Wordsmith,” a writer, ghostwriter, editor, and writing coach speciliazing in transformational modalities and practices. Jordan has helped create cutting-edge works on everything from forensic audio and financial services to health, wellness, psychology, and spirituality. Recent editing credits include Cindy Lou Golin's The Shadow Playbook (2023), Scott Rogers's The Mindful Law Student (2022), and Lawrence Ford's The Secrets of the Seasons (2020).

In this episode of The Psychedelic Podcast, Paul F. Austin is joined by James Fadiman, PhD, and Jordan Gruber, JD, co-authors of the new book Microdosing for Health, Healing, and Enhanced Performance. Find full show notes and links here: https://thethirdwave.co/podcast/episode-318/?ref=278 Widely recognized as the father of modern microdosing, Jim returns alongside Jordan to challenge outdated pharmaceutical paradigms and share what a decade of real-world microdosing reports reveals about physical health, emotional wellbeing, and performance enhancement. James Fadiman, PhD, is a leading voice in psychedelic research, widely known as the “father of microdosing.” With a career spanning over 60 years, Jim has explored psychedelics' effects on creativity, mental health, and human potential. His landmark book, The Psychedelic Explorer's Guide, remains a foundational text in the field. In recent years, he's spearheaded citizen science efforts on microdosing, gathering thousands of real-world reports to better understand its therapeutic and performance-enhancing effects. Jordan Gruber, JD, MA, is a writer, editor, and former attorney whose work bridges psychology, spirituality, and personal development. Founder of Enlightenment.Com, Jordan has collaborated on books covering everything from finance to forensic audio to transformational healing. He co-authored Your Symphony of Selves with Fadiman in 2020 and now returns as co-author of their latest work. Together, their partnership blends rigorous inquiry with lived insight—shaping a new paradigm for how psychedelics can enhance everyday life. Highlights: Why microdosing works for both healing and performance The real-world shift from symptom-treatment to systemic wellbeing How citizen science is driving the microdosing movement Microdosing vs. psycholytic dosing: Key distinctions Why mainstream research may be missing the sweet spot Comparing protocols: Fadiman vs. Stamets vs. intuitive dosing The myth of the serotonin hypothesis and what comes next Heart risk debates and what the data actually says Microdosing for autism, ADHD, and chronic pain What an ideal regulatory future could look like Episode Links: Jim and Jordan's new book, Microdosing for Health, Healing, and Enhanced Performance Episode Sponsors Psychedelic Coacing Institute's Intensive for Psychedelic Professionals in Costa Rica - a transformative retreat for personal and professional growth. Golden Rule Mushrooms - Get a lifetime discount of 10% with code THIRDWAVE at checkout These show links contain affiliate links. Third Wave receives a small percentage of the product price if you purchase through the above affiliate links.

Archie welcomes Clifton Fadiman to Duffy's for a lecture to a ladies' club. But he doesn't trust the scholarly Fadiman to write his own lecture, so Archie writes it for him.Originally aired on June 15, 1943. This is episode 95 of Duffy's Tavern.Please email questions and comments to host@classiccomedyotr.com.Like us on Facebook at facebook.com/classiccomedyotr. Please share this podcast with your friends and family.You can also subscribe to our podcast on Spreaker.com, Spotify, iTunes, Stitcher, TuneIn, iHeartRadio, and Google podcasts.This show is supported by Spreaker Prime.

Psychedelic researchers James Fadiman and Jordan Gruber discuss microdosing protocols, benefits, current research, and safety considerations. Throughout the interview, you will learn the practical basics of psychedelic microdosing—substances, dosage, frequency and duration, when in the larger arc of our lives, and who would best benefit from microdosing; You will also learn about the benefits of microdosing that Gruber and Faidman discovered in their research, which they describe as A-Z, anorexia to zoster and everything in between—with a particular focus later on in the interview on microdosing for various neurological and mental health conditions like ADHD, TBI, dementia, and depression—as well as for the betterment of well people You'll also learn some of the issues facing microdosing as a both a practice and a premise— issues like placebo, research design, and the potential dangers of microdosing. Enjoy!

In this episode of The Psychedelic Report, Dr. Dave Rabin welcomes renowned experts James Fadiman, PhD, and Jordan Gruber, JD, for a compelling conversation on the science and health significance of microdosing. Together, they explore the historical roots of psychedelics in America and their resurgence in modern medicine, shedding light on how these once-stigmatized substances are now being reexamined for their therapeutic potential.Gain a deeper understanding of what microdosing is, how it works in the brain and body, and the optimal protocols for safe and effective use. This discussion highlights the role of microdosing in enhancing neuroplasticity, reducing inflammation, and supporting mental health—especially for those grappling with treatment-resistant depression. With a mix of scientific insight, real-world experiences, and emerging research, this episode offers valuable takeaways for both newcomers and seasoned explorers of psychedelics.Microdosing for Health, Healing, and Enhanced Performance: http://MicrodosingBook.comTo dive even deeper, check out Your Symphony of Selves by Fadiman and Gruber, and check out our previous discussion on the TPR about microdosing and multiple personalities.Published Microdosing book related interviews and podcasts:https://www.microdosingbook.com/eventsWeb: https://thepsychedelic.reportTwitter: https://twitter.com/DrDavidRabinInstagram: https://www.instagram.com/drdavidrabinWeb: https://www.drdave.io/

JAMES FADIMAN, PhD, has been professionally involved with psychedelics for over 60 years. He developed modern microdosing, including the use of protocols, specific dose ranges, and time off. He is the author of The Psychedelic Explorer's Guide (2011) and is the world's foremost microdosing researcher. JORDAN GRUBER, JD, co-author of Your Symphony of Selves with Fadiman in 2020, has written, ghost written, and edited over a dozen books in a wide variety of fields including psychology, spirituality, finance, and personal development. He has been close friends with Fadiman since 1990 and contributed to The Psychedelic Explorer's Guide.

What if ancient myths are warnings for the future? Contemporary folklorist Lauren Fadiman explores how the Norse tale of Ragnarök may stem from real climate catastrophe, revealing how folklore preserves lessons of resilience and can guide how we adapt to our own time of crisis. Hosted on Acast. See acast.com/privacy for more information.

What if ancient myths are warnings for the future? Contemporary folklorist Lauren Fadiman explores how the Norse tale of Ragnarök may stem from real climate catastrophe, revealing how folklore preserves lessons of resilience and can guide how we adapt to our own time of crisis.

What if ancient myths are warnings for the future? Contemporary folklorist Lauren Fadiman explores how the Norse tale of Ragnarök may stem from real climate catastrophe, revealing how folklore preserves lessons of resilience and can guide how we adapt to our own time of crisis.

James Fadiman and Jurgen Gruber discuss their book Microdosing for Health, Healing, and Enhanced Performance.

Episode 04: Jim Fadiman and Jordan Gruber - Microdosing: Everything you need to know James Fadiman, PhD and Jordan Gruber, JD have just released a new book called 'Microdosing: FOR HEALTH, HEALING AND ENHANCED PERFORMANCE' and this episode of the podcast takes a deep dive with both Jim and Jordan into the seemignly magical applications of microdosing psychedelic compounds. The conversation covers all the essential information if you are considering microdosing and uncovers the vast array of conditions that microdosing might be helpful in treating. If you're interested in this end of the psychedelic spectrum - look no further. JAMES FADIMAN, PhD, has been professionally involved with psychedelics for over 60 years. He developed modern microdosing, including the use of protocols, specific dose ranges, and time off. He is the author of The Psychedelic Explorer's Guide (2011) and is the world's foremost microdosing researcher. JORDAN GRUBER, JD, co-author of Your Symphony of Selves with Fadiman in 2020, has written, ghost written, and edited over a dozen books in a wide variety of fields including psychology, spirituality, finance, and personal development. He has been close friends with Fadiman since 1990 and contributed to The Psychedelic Explorer's Guide.

I am joined in this podcast by Anne Fadiman to discuss her classical book The Spirit Catches You and You Fall Down, her account of the cross-cultural conflicts between a Hmong family and the American medical system. The book won a National Book Critics Circle Award, a Los Angeles Times Book Prize, and a Salon Book Award.Published in 1997, the book has attained classic status within medicine. Its contents and lessons remain relevant for contemporary medical practice, and this is why I listed it amongst the important book's this podcast explores.Anne explored the tragedy that evolved when Hmong refugees in the United States interacted with their health centre. At the centre of the saga is their young daughter with refractory epilepsy. Anne explores the transcultural failures that marred the interactions between the two sides, and almost fatally compromised the girl's life.Anne Fadiman is Professor in the Practice of Creative Writing, and Francis Writer-in-Residence at Yale University. The former editor of The American Scholar and a fellow of the American Academy of Arts and Sciences, Fadiman is also the author of two essay collections, Ex Libris and At Large and At Small, and a memoir, The Wine Lover's Daughter.

James Fadiman courtesy of Scott Kline Entheo*Anarcho*Animism / Endogenous Indigenuity Caroline is wildly enthused to welcome James Fadiman, PhD Who writes: “The work most worth doing for me has been helping myself and others remember how interwoven we are with the rest of the natural world. Only when we act out a dark fantasy of separation do we harm the very world in which we are enmeshed. Once awakened, exploitation of others, the destruction of any eco- system and that ultimate obscenity – war – all become as impossible to support as it would be to take a hammer and chisel (and) cut off one's own fingers. My different forms of self-expression: work, writing, photography are parts of who I have been and am. Psychedelic experiences have been the foundation stones of my worldview, as crucial now as when I had my first experience. If it is true, as one tradition suggests, that “God is as close to you as your jugular vein,” knowing that personally should be beneficial.” https://www.jamesfadiman.com/ connects to https://microdosingpsychedelics.com/ Support The Visionary Activist Show on Patreon for weekly Chart & Themes ($4/month) and more… *Woof*Woof*Wanna*Play?!?*   KPFA in Fund Drive The Psychedelic Exoporer's Guide = (for a pledge to KPFA of $100) Called “America's wisest and most respected authority on psychedelics and their use,” James Fadiman has been involved with psychedelic research since the 1960s. The Psychedelic Explorer's Guide addresses the immediate and long-term effects of psychedelic use for spiritual (high dose), therapeutic (moderate dose), and problem-solving (low dose) purposes. Fadiman outlines the best practices for safe, sacred entheogenic voyages learned through his more than 40 years of experience–from the benefits of having a sensitive guide during a session (and how to be one) to the importance of the setting and pre-session intention. James Fadiman reviews the newest as well as the neglected research into the psychotherapeutic value of visionary drug use for increased personal awareness and a host of serious medical conditions, including his recent study of the reasons for and results of psychedelic use among hundreds of students and professionals. He reveals new uses for LSD and other psychedelics, including extremely low doses for improved cognitive functioning and emotional balance. Cautioning that psychedelics are not for everyone, he dispels the myths and misperceptions about psychedelics circulating in textbooks and clinics as well as on the internet. Exploring the life-changing experiences of Ram Dass, Timothy Leary, Aldous Huxley, and Huston Smith as well as Francis Crick and Steve Jobs, James Fadiman shows how psychedelics, used wisely, can lead not only to healing but also to scientific breakthroughs and spiritual epiphanies. The post The Visionary Activist Show – Entheo*Anarcho*Animism appeared first on KPFA.

Paris, 1961: Ram Dass gives James Fadiman a pill that changes his life. In this episode of Plantscendence, we sit down with pioneering researcher and author, Dr. James Fadiman, who is widely recognized for his groundbreaking work on microdosing psilocybin. Listeners are transported to 1961 Paris, where Dr. Fadiman recounts his initial exposure to psychedelics with his mentor, Richard Alpert (later to become Ram Dass), and the subsequent shift in his perception of reality.  He tells the story of how he first came to research psychedelics at Stanford, and how these early experiments at the lab in Menlo Park eventually paved the way for him to develop the first modern microdosing protocols.  The episode touches upon the historical context of entheogens, including the CIA's covert involvement in psychedelic research and the drugs' sudden prohibition during the Nixon era. Dr. Fadiman also reflects on recent shifts in societal attitudes towards psychedelics, and their potential to treat a variety of mental and physical illnesses.Plantscendence.com

Expert James Fadiman explains how psychedelics have the power to expand consciousness, enhance creativity, and deepen our connections to the world. James Fadiman, a distinguished figure with over six decades in psychedelic research, examines the profound impact psychedelics have on consciousness, creativity, and connectivity. Fadiman shares insights into how these substances shift perception, offering perspectives that challenge and expand our understanding of reality. He also delves into the scientific underpinnings of psychedelics, their therapeutic potential, and the societal benefits of fostering deeper empathy and open-mindedness. Highlighting the importance of integration post-experience, Fadiman sheds light on the transformative power of psychedelics to not only alter individual consciousness but also to enhance community bonds and personal relationships. Through a focus on responsible use and the expansion of human awareness, Fadiman's expertise offers a compelling view into the capacity of psychedelics to redefine our interaction with the world and ourselves. We created this video in partnership with Unlikely Collaborators -------------------------------------------------------------------------------------------------------------------------------------------------------------------- Go Deeper with Big Think: ►Become a Big Think Member Get exclusive access to full interviews, early access to new releases, Big Think merch and more ►Get Big Think+ for Business Guide, inspire and accelerate leaders at all levels of your company with the biggest minds in business -------------------------------------------------------------------------------------------------------------------------------------------------------------------- About James Fadiman: Dr. James Fadiman is a leading scientific expert on the use of psychedelics for personal exploration, healing, and transformation. He has been researching, writing and lecturing on the topic for more than fifty years. His research focuses on exploring the potential of psychedelics to help individuals achieve a more meaningful, balanced and enlightened life. He has written numerous books on the topic, such as The Psychedelic Explorer's Guide and Your Symphony Of Selves, and is widely considered to be one of the most influential figures in the field. -------------------------------------------------------------------------------------------------------------------------------------------------------------------- About Big Think | Smarter Faster™ ► Big Think The leading source of expert-driven, educational content. With thousands of videos, featuring experts ranging from Bill Clinton to Bill Nye, Big Think helps you get smarter, faster by exploring the big ideas and core skills that define knowledge in the 21st century. Get Smarter, Faster. With Episodes From The Worlds Biggest Thinkers. Follow The Podcast And Turn On The Notifications!! Share This Episode If You Found It Valuable Leave A 5 Star Review Learn more about your ad choices. Visit megaphone.fm/adchoices

James Fadiman did his dissertation on the effectiveness of LSD-assisted therapy. He has held a variety of positions: teaching (San Francisco State, Brandeis, and Stanford), consulting, training, counseling and research, and taught in psychology departments, design engineering, and for three decades, at the Institute of Transpersonal Psychology (now Sofia University) that he co-founded. Dr. Fadiman has published textbooks, professional books, a self-help book, a novel, and a series of videos, ‘Drugs the children are choosing for National Public Television'. His books have been published in 8 languages. He was featured in a National Geographic documentary and had three solo shows of his nature photography. Dr. James had his own consulting firm and has been the president of a natural resource company and has been involved in researching psychedelics for spiritual, therapeutic, and creative uses and is best known for his work on microdosing. He has published The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys, and is working on a book about microdosing.Episode Highlights▶ 00:05 Welcome▶ 00:37 James Fadiman's extensive background in the psychedelic study and research▶ 02:29 The origin story of Fadiman's personal psychedelic journey▶ 04:37 Exploring the concept of microdosing▶ 08:47 The many positive impacts of microdosing on daily life▶ 13:25 Different microdosing protocols▶ 17:52 The future of microdosing and its potential impact on humanity▶ 23:55 The role of psychedelics in increasing societal environmental awareness▶ 27:59 The impact of capitalism in the psychedelic space▶ 30:54 The ethical use and propagation of psychedelics▶ 36:37 Psychedelics and the law▶ 39:28 Microdosing and anecdotal evidence of impacts on physical health▶ 47:14 The future of microdosing research James Fadiman's Links & Resources▶ Website: https://www.jamesfadiman.com/▶ Facebook: https://www.facebook.com/james.fadiman▶ Twitter: https://twitter.com/Jfadiman

It's a strange paradox, but there is Infinite power in peace. Franci, a kindred free spirit, courageously shares her brave journey overcoming religious trauma. We talk in-depth about the transformative nature of awe and travel, the science of meditation to rewire our brains and nervous systems, why breathwork is a game-changer, gradual cold exposure, how to get the most out of a contemplative journaling practice, microdosing and macrodosing, and the supreme importance of integration practices to cultivate health, happiness, strength and resilience from within. Lastly, Franci shares her incredible bucket list Thailand Meditation Retreat.    Franci Blanco Show Notes:   We discuss;    -Franci's inspiration for her unconventional path: Awe & Travel [10:00] -Yoga teacher training and the power of the breath [15:10] -Religious trauma [18:10] -Do it afraid [27:00] -Incredible science of meditation [31:50] -Franci's meditation practice and Vipassana Retreats [42:25] -RAIN: Recognize, Allow, Investigate, Nurture [52:00] -Power of contemplative journaling [55:20] -Breathwork: Wim Hof & NSDR [1:02:20] -Franci's psychedelic journey and microdosing for depression [1:25:15] -Thailand Meditation Retreat [1:33:15] https://www.happyheartsyogaproject.com/retreats   Helpful Resources: Calm App: https://www.calm.com Wim Hof Method: https://www.wimhofmethod.com NSDR Guided Breathwork: https://youtu.be/AKGrmY8OSHM?si=Cn9Ozlk3UrXckKK1   Connect with Franci Blanco: IG: https://www.instagram.com/franciprana/ Website/Thailand Meditation Retreat: https://www.happyheartsyogaproject.com/retreats Breath Tribe Miami: https://www.breathtribemiami.com   Connect with Matt Simpson:  Worth The Fight Book: Kindle, Audiobook & Paperback  www.worththefightbook.org  IG @worththefightbook Meetup: https://www.meetup.com/psychedelics-and-limitless-personal-growth/ matt@nltrans.org 

Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture.  This week Anne Donohoe is back, alongside first time-host - longtime producer (sorta!) and fellow KCSAer Emmaline Lewis, for a new episode with special guests Jim Fadiman, PhD, Independent Microdosing Researcher known as the “Father of Microdosing” and author of numerous books, textbooks and more; and Adam Bramlage, Founder of Flow State Micro, the leader in microdosing supplements, education and community.  Jim and Adam join us this week to discuss microdosing nuances, their shared talk at Psychedelic Science 2023, Microdosing: Remarkable results, surprising implications, Flow State Micro's virtual workshop offerings and what goes into Adam's 1-on-1 mentorship program, the top microdosing misconceptions, and what psychedelic legalization might look like. If you are interested in learning more about Dr. Fadiman, his books, or Flow State Micro and its variety of offerings, visit the links in our show notes. Also, be sure to follow Adam and Flow State Micro on Instagram and LinkedIn. So sit back and enjoy our conversation with Dr. Fadiman, Independent Microdosing Researcher, and Adam Bramlage of Flow State Micro.  Links and mentions in the show Jim Fadiman, PhD: https://jamesfadiman.com/ Jim Fadiman, PhD, recent books: Your Symphony of Selves: https://jordangruber.com/your-symphony-of-selves The Psychedelic Explorer's Guide: https://www.psychedelicexplorersguide.com/ COMING SOON: new book set to publish early 2025 Flow State Micro: www.FlowStateMicro.com   Links to the guest's company and social media accounts Flow State Micro Instagram: https://www.instagram.com/flowstatemicro/ Adam Bramlage LinkedIn: https://www.linkedin.com/in/adam-bramlage-615819164/   Show Credits: This episode was hosted by Anne Donohoe and Emmaline Lewis of KCSA Strategic Communications.  Special thanks to our Program Director Shea Gunther. You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels: Twitter: @The_GreenRush Instagram: @thegreenrush_podcast LinkedIn: https://www.linkedin.com/company/thegreenrushpodcast/ Facebook: https://www.facebook.com/TheGreenRushPodcast/  YouTube: https://www.youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true

This is my personal journey with microdosing Iboga. Week 1 (Day 1).My first dose is 0.125mg (not micrograms as I incorrectly said). That's about a 20th of a standard dose to be hallucinogenic.The idea with microdosing is to be able to function normally but be perhaps more focussed and creative, and perhaps to release fears and feel more grounded (that's iboga's forte). It is the root bark of the African shrub Tabernanthe iboga (so I was both right and wrong!)Please note these videos in no way reflect my professional work and are a frank and honest account of experimenting with this new therapy intended to help people with intractable problems like anxiety and depression. As I have suffered from anxiety all my life, it seems like something worth trying.James Fadiman's Microdosing info - https://microdosing.com/ *If you're suffering from Chronic pain, fatigue or anxiety, I CAN HELP*CONTACT ME: https://www.alchemytherapies.co.uk/Alchemy Therapies & Emotional MasterclassOTHER USEFUL RESOURCESGroup Healing Program: http://myemotionalaudit.comAuthor/Book site: https//patriciaworby.comPodcast: https://www.alchemytherapies.co.uk/po...121 and group therapy and training for stress related conditions like anxiety, fatigue and pain: https://alchemytherapies.co.ukSee in particular: Thrive! - an introductory mindbody connection program and The Emotional Audit for more intensive training.COMING SOON:Intensive Training Program: https://emotionalmasterclass.com

For access to the full Sus Psychedelics, Inc. series and other premium episodes, subscribe to the Al-Wara' Frequency at patreon.com/subliminaljihad. PHASE FOUR: THE CLINICAL FINISH LINE Dr. Roland Griffiths and the Johns Hopkins Psilocybin Study, using psychedelics to lower the fear response and confront death, the incredibly revealing 1979 “A Conversation on LSD” reunion video featuring Tim Leary, Humphrey Osmond, Oscar Janiger, Al Hubbard, Willis Harmon, Myron Stolaroff, and Laura Huxley, talking about Allen “indefatigable Zionist for drugs” Ginsberg, the necessity of “shaking things up” a bit, “The Search for the Manchurian Candidate” by John Marks… The Institute of Noetic Sciences and the Crockers, Michael Pollan's “How To Change Your Mind” turning on the soccer moms, Leary's writings on Egg Intelligence and the Termite Queen Gaia Religion of the future, influencing the influencers… The Temple of the People in Halcyon, CA, Master Hilarion and the Theosophical roots of Silicon Valley, Steiner's warnings about Ahrimanic transhumanism, the Halcyon-raised Varian Brothers and Lytton Industries, moving into klystron & microwave tube production for the Pentagon, the rise of semiconductor manufacturing in the Valley, the evolutionary element known as Timothy Leary imagining himself as the reincarnation of G.I. Gurdjieff and Aleister Crowley… Leo Zeff biographer/LSD pioneer Myron Stolaroff's substantial engineering career in Silicon Valley, getting mentored by Fred Terman at Stanford, Lewis Terman's psychedelic protege Betty Eisner, the International Foundation for Advanced Study, the revolutionary Ampex Model 300 tape recorder that took Hollywood by storm, Bing Crosby, the staggeringly innovative output of Ampex alumni including Atari, Pixar, Dreamworks, Apple, Dolby Surround Sound, Larry Ellison and the CIA-contracted Project Oracle, sus microdosing advocate Jim Fadiman's work at IFAS, SRI-ARC, and Esalen, taking shrooms with dirtbag groomer Ram Dass in Paris, Fadiman's gifted child cousin William James Siddis, the “not upsetting, but kind of opening” nudist romps at the Esalen baths, mycologist heir Alan Rockefeller, Col. James Ketchum's work at the Edgewood Arsenal and Haight Ashbury Free Clinic… The ayahuasca murder/lynching saga of Sebastian Woodruff, the LSD/ketamine-fueled, con artist guru-assisted death of Malibu eye surgeon Mark Sarwusch, and a brief look at shaman to the stars Mike “Zappy” Zapolin, who says ketamine is an evolutionary technology that will help us make contact with alien intelligences.

Psychedelic pioneer and living legend Dr. James Fadiman shares his expansive wisdom on how to get the most out of an intentional microdosing protocol. There is an explosive cultural phenomenon of people using “micro” doses of psychedelic medicine to boost mood and energy levels; Dr. Fadiman breaks down why and the mechanism at play here, illuminating the wondrous Possibility in microdosing for health, well-being, expansive creativity, and deeper connection(s).  Show Notes Dr. James Fadiman:  We Discuss; -Massive surge in microdosing: Cultural phenomenon [6:30] -Microdosing for depression [9:30] -Microdosing and Connection/Sex/Intimacy [12:00] -Neuroplasticity: Massive leverage point [15:30] -“Start low, go slow & take time off” [16:45] -Safety of psychedelics and microdosing [18:00] -Placebo effect [24:00] -Pharma's failure: Depression keeps rising [33:00] -Fadiman's pioneering psychedelics for creativity studies from 1960s [34:30] -Practice of envisioning [41:30] -Psychedelics vs. Pharma model [47:20] -Dr. Fadiman's latest book: Your Symphony of Selves [54:00]   Connect with Dr. James Fadiman:   https://www.jamesfadiman.com https://www.psychedelicexplorersguide.com https://jordangruber.com/your-symphony-of-selves  

Anne Fadiman unpacks her latest essay, “Frog,” a 6,000-word piece about Bunky, her family's African clawed frog. Although he was easy to care for, this “unpettable pet” raised a number of philosophical and ethical questions about pet ownership. For nearly two decades, Bunky lived inside a too-small aquarium on Fadiman's kitchen counter, ribbitting for a mate that could never come. Fadiman probes her continued guilt over whether this animal had lived a decent life—after all, you can't spay or neuter a pet frog. Suffused with this unease, Fadiman's essay departs from the typically saccharine or sentimental approach to writing about pets and death, respectively. As she explains in this episode, “Death is hard to face, so it's interesting to face. It's a literary challenge. And not all deaths are the same.” Bunky's departure lends lessons on writing, caretaking, connections, confinement—in a word, relationships. Read Fadiman's essay: https://harpers.org/archive/2023/03/frog-what-happens-to-the-pets-that-happen-to-you/ Subscribe to Harper's for only $16.97: harpers.org/save This episode was produced by Violet Lucca and Maddie Crum, with production assistance by Ian Mantgani.

Episode 167 Notes and Links to Mai Der Vang's Work         On Episode 167 of The Chills at Will Podcast, Pete welcomes Mai Der Vang, and the two discuss, among other things, her childhood as bilingual and a voracious reader, formative writers and writing in her life, catalysts to write about Hmong culture, and specifically the towering achievement that is Yellow Rain, with its depiction of an often-dehumanized and preyed upon people and other pertinent issues of empire and colonization.      Mai Der Vang is the author of Yellow Rain (Graywolf Press, 2021), winner of the Lenore Marshall Poetry Prize from the Academy of American Poets, an American Book Award, and a finalist for the 2022 Pulitzer Prize in Poetry, along with Afterland (Graywolf Press, 2017), winner of the First Book Award from the Academy of American Poets. The recipient of a Lannan Literary Fellowship, her poetry has appeared in Tin House, the American Poetry Review, and Poetry, among other journals and anthologies. She teaches in the MFA Program in Creative Writing at Fresno State.            Buy Yellow Rain   Mai Der Vang's Website   “Review: YELLOW RAIN – Mai Der Vang (Graywolf Press),” by Ronnie K. Stephens, The Poetry Question, November 18, 2021   Interviews/Press for Mai At about 6:40, Pete and Mai Der shout Fresno stars like Lee Herrick, Juan Felipe Herrera,    At about 8:00, Mai gives background on her reading and language relationships, starting from childhood, and leading to an overview of her multigenerational family background and Hmong as her first language    At about 12:00, Mai responds to Pete's question about representation for Hmong people in the literary world, including the awkward links to Fadiman's The Spirit Catches You and You Fall Down   At about 16:15, Mai discusses writers and writing that have been “game-changers” for her, including the work of Juan Felipe Herrera, Cathy Park Hong, Solmaz Sharif, and Douglas Kearney   At about 19:00, Pete asks Mai about any “ ‘Eureka' moments” that have guided her into writing as a profession; she cites the Hmong Community Writers' Collective as a guiding force    At about 21:35, Mai answers Pete's questions about ideas of dialogue and silence in Hmong communities regarding the “Secret War” and its aftermath    At about 24:15, Pete outlines Yellow Rain's opening and asks Mai about “following the rains”-she details her research (10 years!)   At about 25:05, Pete refers to a review of the book from The Poetry Question saying the book “defies genre”-Pete asks about goals in mind for the book, regarding its unique and diverse styles   At about 27:40-34:05, Pete cites the Wikipedia article regarding “Yellow Rain” and asks Mai for a background on it in connection to the Hmong and their lives post-”Secret War”   At about 34:05, Pete quotes from and asks about some of the collection's early poems and refers to ideas of the Hmong as disregarded; Mai discusses an oft-quoted line about “gardening”   At about 36:20, Pete and Mai make comparisons between Roberto Lovato's incredible work with Unforgetting and Mai's work   At about 37:10, Pete and Mai discuss a disastrous and racist Radiolab interview regarding the Hmong and yellow rain    At about 39:00, Pete and Mai discuss the theme of dehumanization that runs throughout her collection    At about 40:40, Mai talks about the ineptitude and missteps that led to an inability to make definitive proclamations about yellow rain's provenance    At about 44:05, The two discuss the double meanings of “specimen” and the ways in which a possible chemical weapon used against the Hmong was incredibly destructive and hard to trace   At about 45:30, The bees are investigated and discussed-ideas that bee feces may have been the reason for the yellow mist were put forth   At about 49:00, Ideas of colonization and American empire are investigated via the book's poems    At about 52:35, Pete reads a line that sums up so profoundly ideas of “what if's” and    At about 53:50, Mai talks about ideas of resistance and about any possible political and cultural actions-i.e., the future and any advocacy    At about 59:00, Mai reads the last poem of the collection, “And Yet Still More” and discusses some key lines    At about 1:02:55, Mai gives contact and social media info     You can now subscribe to the podcast on Apple Podcasts, and leave me a five-star review. You can also ask for the podcast by name using Alexa, and find the pod on Stitcher, Spotify, and on Amazon Music. Follow me on IG, where I'm @chillsatwillpodcast, or on Twitter, where I'm @chillsatwillpo1. You can watch other episodes on YouTube-watch and subscribe to The Chills at Will Podcast Channel. Please subscribe to both my YouTube Channel and my podcast while you're checking out this episode.    Sign up now for The Chills at Will Podcast Patreon: it can be found at patreon.com/chillsatwillpodcastpeterriehl          Check out the page that describes the benefits of a Patreon membership, including cool swag and bonus episodes. Thanks in advance for supporting my one-man show, my DIY podcast and my extensive reading, research, editing, and promoting to keep this independent podcast pumping out high-quality content!    This is a passion project of mine, a DIY operation, and I'd love for your help in promoting what I'm convinced is a unique and spirited look at an often-ignored art form.    The intro song for The Chills at Will Podcast is “Wind Down” (Instrumental Version), and the other song played on this episode was “Hoops” (Instrumental)” by Matt Weidauer, and both songs are used through ArchesAudio.com.    Please tune in for Episode 168 with Dur e Aziz Amna. She is from Rawalpindi, Pakistán, now living in Newark, NJ, her work has appeared in the New York Times and Al Jazeera, among others; was selected as Forbes 30 Under 30 in 2022; her standout debut novel is American Fever.    The episode will air on February 21.  

With a bachelor's degree from Harvard University and Ph.D. from Stanford, James Fadiman has dedicated his career to researching psychedelics. After more than 60 years in the field, he's authored The Psychedelics Explorer's Guide, along with other books on psychology. In this episode, we sat down with Dr. Fadiman to discuss the safety and effectiveness of using psychedelics for the treatment of mental illness, the dos and don'ts of macro- and microdosing, the dissolution of the Ego, and more.   To learn more about our Awake + Aware series visit here: https://www.wildhealthsummit.com/awake-and-aware

Two microdosing experts come together today to bring you a wealth of information on microdosing psychedelics. It was an honor to have Dr. Jim Fadiman, a psychedelic heavyweight, and Adam Bramlage, microdosing coach, on today. This conversation goes beyond the basics to deepen your awareness around the practice of microdosing, and affirms that we the people are taking back our power and right to psychedelic substances. Microdosing Masterclass with Dr. Fadiman & Adam on Psychedelics TodayTopics covered in this episode:Citizen science and it's crucial role in the microdosing movementResearch into microdosing psychedelicsThe “mechanism” behind microdosingHistorical use of microdosing and ancestral links to microdosing practicesPsychedelics for wellness, recreation, and human optimizationHow to maximize results on a microdosing protocolThe correct dose for microdosing and finding your sweet spotStacking microdoses with other mushrooms and supplementsEpisode Links:Flow State Micro, Adam's companyConnor Murray Microdosing LSD StudyMicrodosing Masterclass with Dr. Fadiman and Adam [affiliate link]A Really Good Day by Ayelet Waldman [book]The Psychedelic Explorers Guide by Dr. Jim Fadiman [book]Esalan Microdosing Event with Dr. Fadiman & AdamEmail Dr. Fadiman with your microdosing story: jfadiman@gmail.comHave you gained new insights and perspectives from us and our guests? Donate to the podcast via PayPal to help support to cost of creating this powerful content ad-free.If this episode sparked something within, please let me know and leave a review! 1:1 Coaching with LanaInstagram | Facebook  | WebsiteModern Psychedelics Integration JournalDISCLAIMER: Modern Psychedelics does not endorse or support the illegal consumption of any substances. This show is meant for entertainment purposes only. The thoughts, views and opinions on this show should not be taken as life advice, medicinal advice, or therapeutic guidance. This episode was produced in collaboration with FWI Media. Check out their beautiful work! If this episode sparked something within, please let me know and leave a review! FREEBIES to support your journey 1:1 Coaching with LanaInstagram | YouTube | Web | Facebook DISCLAIMER: Modern Psychedelics does not endorse or support the illegal consumption of any substances. This show is meant for entertainment purposes only. The thoughts, views and opinions on this show should not be taken as life advice, medicinal advice, or therapeutic guidance.

Adam Bramlage is Founder and /CEO of Flow State Micro, a functional mushroom company and microdosing education platform. Adam has helped hundreds of people, from professional athletes to people suffering from addiction and depression, achieve results through microdosing in his private practice. This interview gives the basics of microdosing; it's a great primer for anyone just at the beginning of their journey. Adam will be hosting a webinar with psychedelic pioneer and the father of modern microdosing Dr. James Fadiman, PhD, live from Esalen on January 14th. It's called Microdosing: The Safe, Surprising and Emerging Psychedelic Frontier. To sign up go to https://www.esalen.org/learn/esalen-digital-microdosing-the-safe-surprising-and-emerging-psychedelic-frontier-011423 I highly recommend it, as you'll see from this interview, Adam is very skilled at delivering information designed to make any microdosing experience smart, secure and safe. And Dr. James Fadiman is simply an Esalen treasure. He's been a guest on this show before, a couple years back, in an episode called "A Psychedelic History Lesson." Dr. Fadiman was also one of the very first workshop leaders at Esalen - he helped lead a workshop in 1962 entitled "Drug Induced Mysticism" and he's been a meaningful figure at Esalen ever since.

本期节目的嘉宾是我们的朋友外码师傅。外码师傅在北美读人类学的博士项目，她研究的的方向是医学人类学。医学影响着我们生活的方方面面。我们在生活中小到作息起居大到生老病死的决定，无疑不体现着我们对身体、生命、健康、疾病的理解。是什么塑造了我们对医学与生命的理解？我们被“科普”的对疾病的诊断和治疗的方式在何种程度上是一种文化现象，何种程度上是科学？当治疗疾病的药物作为商品流通时，商业模式的全球化又如何影响了我们对于药物与治疗的理解？从文化与科学的关系开始，外码师傅在本期的节目中从医学人类学的角度讨论了如何从文化的角度理解我们自己的身体，医药生产及推广的过程，以及这样的过程如何利用并重塑了我们对疾病的文化理解。本期嘉宾外码师傅内容提要+精彩预告01:01 什么是医学人类学？03:05 人类学视角中的自然和文化：我们认为什么属于文化、什么不属于文化的观点就是文化的一部分“科学也是文化，是一种非常强势的文化”07:00 外码师傅对医学人类学感兴趣的契机12:10 生病的人和家属面对疾病时的感受是什么？会有什么情绪？《疾痛的故事》阿瑟·克勒曼16:40 生病、治病过程中医生的角色“医学人类学关注系统、制度、关系中的人”24:20 医学中的文化冲突“医生和患者的沟通被文化影响”“文化也影响人们对医学的需要和看法”“疾病也是一种社会文化现象，反映了个人在社会生活中面对的问题”27:40 比如：把巫术作为一种手段31:10 当人们对于医学的理解不一样时，医学人类学视角中什么是“真实”？ “医学人类学关注对于一群人来说什么是真实”33:45 外码师傅的研究：热气“热气和上火所关注的东西是不一样的”王老吉的例子“上火借用商业逻辑超越热气的本土语境”41:00 外码师傅的研究：中医药生产的全球化Local biologies本土知识如何全球化？“资本主义也是一种文化体系”“经济逻辑在和中医体系打交道”51:30 阿胶生产的全球化世界各地会有各自的对中医的理解，有不同的中药现象57:00 医学人类学会帮助研究者如何理解自己的身份、自己的生活？“有意识地培育、感受、理解自己的身体是一件很有意义的事情”01:01:35 医学人类学著作推荐《医学人类学十二论》朱剑峰《疾痛的故事》阿瑟·克勒曼《照护》阿瑟·克勒曼《苦痛和疾病的社会根源》阿瑟·克勒曼参考资料Kleinman, A. (2020). The illness narratives: Suffering, healing, and the human condition. Basic books. 《疾痛的故事》Kleinman, A. (2020). The soul of care: the moral education of a husband and a doctor. Penguin.《照护》 Kleinman, A., Anderson, J. M., Finkler, K., Frankenberg, R. J., & Young, A. (1986). Social origins of distress and disease: Depression, neurasthenia, and pain in modern China. Current anthropology, 24(5), 499-509.《苦痛和疾病的社会根源》Fadiman, A. (2012). The spirit catches you and you fall down: A Hmong child, her American doctors, and the collision of two cultures. Macmillan.朱剑峰. (2021).《医学人类学十二论》上海教育出版社.播客 世界莫名其妙物语：https://www.xiaoyuzhoufm.com/podcast/5ec74981418a84a046d8a006片头片尾音乐《Sunrise at Seaside》by 王乾-----------双重意识是一档「让我们认识到那些我们以为此时此刻与我们生活需求没有关联的东西其实和我们紧密相关」的播客节目。你可以在苹果播客, 喜马拉雅，网易云音乐，荔枝fm，小宇宙APP和Spotify搜索"双重意识DoubleConsciousness"找到我们，关注我们并收听我们的节目。欢迎大家在微信后台或是微博(@双重意识DoubleConsciousness)等各大平台给我们留言、提供反馈意见。

Today we welcome Dr. Jim Fadiman. Jim is a psychologist, writer, and lecturer who has been pioneering psychedelic research since the 1960s. He is recognized as “America's wisest and most respected authority on psychedelics and their use.” Jim received his bachelor and doctorate degrees from Harvard and Stanford respectively. Apart from psychedelics, he has also been involved in researching healthy multiplicity for over 20 years. His newest book with Jordan Gruber is called Your Symphony of Selves: Discover and Understand More of Who We Are.In this episode, I talk to Dr. Jim Fadiman about multiple selves. The DSM says that having multiple personalities is a disorder, but Dr. Fadiman challenges this notion. In fact, he believes that the opposite is true: the multiplicity of selves is both normal and healthy. It's not about having one “super self”, but unifying the different parts of who we are. We also discuss psychedelics, its effects on mental health, and how Abraham Maslow would have viewed these mind-altering substances.Website: jamesfadiman.comTwitter: @jfadiman Topics04:54 Modern microdosing06:49 Microdosing for physical and mental health 10:00 Healthy vs pathological multiplicity14:14 What would Maslow think of psychedelics?23:24 No single self 26:42 Taking responsibility for all yourselves30:13 Harmonizing selves34:28 Is it possible to create a super self?38:04 All your parts are you42:14 Unified self is healthy 44:14 Being in the right mind at the right time51:24 Practice selves work

In this episode, Kyle interviews Doctors James Fadiman, Sam Gandy; and David Luke. They discuss Fadiman's past research and Gandy and Luke's new paper, "Psychedelics as potential catalysts of scientific creativity and insight." www.psychedelicstoday.com

In this 3-part series on microdosing, we explore the science, history, and its clinical potential. The anecdotal benefits of microdosing include better mood, creativity, and increased focus. But there are still many unanswered questions that remain. What is an effective dosing protocol? Is it safe in long term use? Does it even work or is it a placebo effect?In part 1, we chat with James Fadiman, Ph.D who has been researching psychedelics since the 1960's. He's the author of several books, including the Psychedelic Explorer's Guide. He has collected thousands of microdosing reports and even has his own microdosing protocol - called the Fadiman protocol. When we talk about standing on the shoulders of giants, James Fadiman is one of them.Credits: Created by Greg Kubin and Matias SerebrinskyHost:  Greg Kubin Produced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack FrankLinks to topics discussed in this episode:Jim's microdosing websiteSofia UniversityThe Psychedelic Explorer's GuidePsychedelics Promote Structural and Functional Neural Plasticity (Ly et al, 2018)

The current interest in using psychedelics for mental health treatment is a ‘back to the future' moment for Dr. Jim Fadiman, a pioneer in psychedelic research known as the father of microdosing. “The method that's been developed for administering high doses in a supervised environment is replicating exactly what we developed in the 1960s,” he tells host Shiv Gaglani.  At that time, the federal government approved his research, but when the Nixon administration criminalized this class of drugs for political reasons, all research stopped, creating a wide belief that they are unsafe when actually, he says, they're among the pharmacologically safest drugs. In the absence of government-sanctioned research, what Fadiman calls “citizen science” has been thriving.  Hundreds of thousands of people have self-reported through social media and other means that the drugs improve their functioning and have no serious side effects. Other countries are sponsoring research yielding the same results. In the context of a deepening mental health crisis, Fadiman believes it makes sense to integrate psychedelics into treatment, especially when the pharmaceuticals in use are only modestly effective for a minority of patients. Make sure to listen through to the end of the episode to learn about his new book, Symphony of Selves on harmonizing different aspects of our personalities to reduce stress and increase empathy for others. This is a deeply-informed, revealing and fun conversation you won't want to miss. Mentioned in this episode:https://www.jamesfadiman.com/

Dr James Fadiman is an American psychologist and writer. Fadiman received a Master's degree and a doctorate in Psychology from Stanford University back in 1960. His friend and former Harvard undergraduate advisor, Ram Dass (then known as Richard Alpert), introduced him to psychedelics. Fast-forward 60 years and Fadiman is now known and acknowledged for his research and clinical work in psychedelic therapy and microdosing. In this episode:Microdosing: Practice & BenefitsPsychedelics in psychiatryPsychedelics in optimisationHow psychedelics open up the capacity for changeSelf & SelvesSupport the podcast:Support the podcastSupport Mind Medicine Australia's mission:Mind Medicine AustraliaSupport this show http://supporter.acast.com/mind-medicine-australia. See acast.com/privacy for privacy and opt-out information.

Episode: 2177 Clifton Fadiman and the cult of cultivation.  Today, we worship words.

James Fadiman is a true man of many talents. Wikipedia calls him an ‘American writer', but actually, he's worked in multiple fields, from psychology, through to IT and, finally, to psychedelic research.He studied Psychology at Harvard University and obtained a PhD from Stanford University. As a graduate student at Stanford, Fadiman was Stewart Brand's LSD guide on Brand's first LSD trip, at Myron Stolaroff's International Foundation for Advanced Study in Menlo Park, California.He was also part of the team in the psychedelics in problem-solving experiment at the International Foundation for Advanced Study, which was abruptly halted in 1966 together with all the remarkable psychedelic research that was happening in the US. Additionally, Fadiman worked at Stanford's Augmentation Research Center, a division that did research on networked computing. What did the technological research group need a psychologist in their team for? How are psychedelics and technological advances interconnected? And finally, what happens when you give psychedelics to a group of scientists? Listen to this week's episode to find out! Richard Alpert (Baba Ram Dass)PsilocybinTimothy LearyAldous HuxleyInternational Foundation for Advanced StudyMyron StolaroffLSDBrandeis UniversityWillis HarmanPTSDSet and settingMescaline Doug EngelbartThe Mother of All DemosNixon's War on drugsAbraham MaslowMicrodosingmicrodosingpsychedelics.com FDADouble-blind studiesLupus ★ Support this podcast ★

James Fadiman, PhD, was a part of the first wave of pioneering psychedelic researchers in the 1960s in the US. He's the co-founder of the Institute of Transpersonal Psychology, now known as Sofia University, and he's the author of several well-known psychedelics books, including The Psychedelic Explorer's Guide. From his initial rediscovery of microdosing and developing a protocol based on early reports, Dr. Fadiman teamed up with Dr. Sophia Korb to record and pattern-map the microdosing experiences of several thousand individuals from 51 countries. In this episode, Dr. Fadiman answers listener-submitted questions regarding microdosing psilocybin and LSD. He discussed dosing recommendations, tolerance, microdosing's general effects on healthy normals, and its specific effects on a number of conditions, ranging from depression to PMS. He also covered a variety of additional areas where people benefit from microdosing, including academic performance and athletics.  In the last part of the episode, Dr. Fadiman discusses his new book, Your Symphony of Selves. He points out that we have not one, but a multitude of selves, and that we can learn to shift between them consciously. Further following this idea, he illustrates how we can save a lot of mental distress by not over-identifying with any particular one of our selves, and how we can extend that concept to those around us. This helps us not only forgive others when one of their selves may have acted in a displeasing way but also helps us forgive and go easy on ourselves when we act in a way that we later find distressing or shameful.   In this episode: The reported benefits and risks of microdosing psilocybin mushrooms and LSD. Whether someone's height and weight makes a difference on their dosage. The overwhelming number of those suffering from depression who reported significant improvements in their survey. Why microdosing may not be advisable for those with anxiety. Dr. Fadminan reports on study findings regarding conditions including depression, PMS, migraine headaches, and bipolar    Quotes: “A lot of people have found that when they're tapering off of an SSRI, which means taking it down very, very slowly over a period of maybe a couple of months from full dose to zero, that microdosing helps. That makes it easier. Makes it maybe even a little faster.” [14:13] “I'm an enthusiast for the effect of microdosing, but I never recommend that anyone microdose. That's a personal decision based on information, but the nice thing is the risk/reward ratio, which is how dangerous versus how beneficial. It's very good for microdosing. Meaning, if you take it, it's very low risk, and yeah, from the reports, we have a lot of possibility of benefits.” [35:00] “What we've found is that about 80% of the people who come in with heavy depression, and again, most of them having failed medications or other therapies, we've about an 80% turnaround rate where they're not depressed. That's really striking.” [42:00] “They (students) say: “Microdosing is very much like Adderall, except with none of the very disturbing side effects.” Adderall includes crashing, by the way. And addiction.” [49:18] “Individual neurons in the laboratory, exposed to microdoses, grow into more healthy, more complex neurons with more dendrites, meaning more communication capacity.” [52:17] In discussing his new book, Your Symphony of Selves: “The inconsistencies you see in yourself and particularly in the people you love are not inconsistencies. It is that they have several selves, and you do too. And if you begin to think in that way, curiously, the world becomes easier. You understand things differently and you are kinder to yourself and more compassionate to others.” [1:10:43]   Links: Psychedelic Medicine AssociationMicrodosing Psychedelics  James Fadiman's website and email: jfadiman@gmail.com Cluster Busters - treatment for cluster headaches Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Porangui Studies mentioned:Psychedelics Promote Structural and Functional Neural Plasticity Books Mentioned: A Really Good Day by Ayelet Waldman The Psychedelic Explorer's Guide by James Fadiman PhD Your Symphony of Selves by James Fadiman PhD, Jordan Gruber JD

Original airdate: June 15, 1943--- Send in a voice message: https://anchor.fm/w-blaine-dowler2/message See acast.com/privacy for privacy and opt-out information.

In today's episode we have the honor of sitting down to talk with Psychedelic Pioneer and Researcher Dr. James Fadiman!In today's conversation we dive into what got James into psychology and psychedelics in the first place. We go into his first experiences with psilocybin while in Paris with his mentor Richard Albert (now know as Ram Dass) and then his most profound experience he had months later in the US that expanded his consciousness so much that it hasn't contacted since.We dive into the differences between a large dose of psychedelics vs. a micro dose and the benefits for both of them.We talk about how people can use Microdosing in their everyday lives and the positive effects it has on people in their health, mindset and relationships.We go over how Microdosing can benefit people trying to lose weight or perform better in their sports or their career.Then we dive into his most recent book "Your Symphony of Selves" and the idea of multiplicity vs. singular selves. We go deep into the meaning behind this and how it applies to our every day life's!We then talk about how our body reacts when we do not allow these other "selves" to be expressed in our worlds.It was a great pleasure to be able to sit down and have this conversation with Dr. Fadiman and I hope you can take some great insights from our conversation.If you would like to purchase his books you can on Amazon or anywhere else books are sold!-The Psychedelics Explorers Guide: Safe, Therapeutic and Sacred Journeys-Your Symphony of Selves: Discover and Understand more of Who We Are

We talk with Dr. James Fadiman — independent researcher, psychologist, and author of the "Psychedelic Explorer's Guide." We discuss personal transcendent experiences, how often to macrodose, and the guide debate.Highlights— THE NUGGET: the DEA is being sued for legalization of plant medicine (0:35)— THE NOODLE: Preventive care psychedelics for healthy people (1:27)— Thank you, Jim (2:14) — What 2021 Jim would say to 1966 Jim (3:22)— The "George Bush Mission Accomplished" moment for psychedelics (5:06)— What does society look like with ubiquitous plant medicine (7:41)— Jim and Ray's profound experiences on high dose sessions (9:19)— When you return from transcendence (12:12)— When you understand time and the true nature of reality (14:08)— How he discovered the Fadiman microdosing protocol (16:09)— How often to engage larger doses (18:07)— Does everyone need a guide for bigger doses? (21:43)— Integrating with your internal personas (25:58)— SOUL SEARCH: the psychedelic Mt. Rushmore, alien invasions, psychedelic effects in the bedroom, and the meaning of life (28:14)— SLAP and a CLAP: Compass Pathways & Fireside Project (31:56)BioDr. James Fadiman, PhD, holds degrees from Harvard and Stanford, and wrote his dissertation about LSD-assisted therapy. As well as holding consulting, training, counseling and editorial jobs, he has taught psychology and design engineering at San Francisco State, Brandeis, and Stanford and, for three decades, taught Sufism and other classes at Sophia University that he co-founded. He has published textbooks, professional books, a self-help book, a novel, a produced play and videos including: "Drugs: the children are choosing" for National Public Television. He was featured in a National Geographic documentary and had three solo shows of his nature photography. He has been involved in researching microdosing psychedelics since 2010. In addition to the "Psychedelic Explorer's Guide," he most recently wrote "Your Symphony of Selves: Discover and Understand More of Who We Are" (with Jordan Gruber).Find Jim here:https://www.jamesfadiman.com/ ---See the inspiration behind the Psychedelic Diaries here:https://www.textpert.ai/post/the-psychedelic-macrodose-diary-what-you-learn-when-you-journey-inward

Your Symphony of Selves: James Fadiman & Jordan Gruber Why you are a different you at different times and how that's both normal and healthy... Each of us is comprised of distinct, autonomous, and inherently valuable “selves”. They also show that honoring each of these selves is a key to improved ways of living, loving, and working. Instead of seeing the existence of many selves as a flaw or pathology, Gruber and Fadiman reveal that the healthiest people, mentally and emotionally, are those that have naturally learned to appreciate and work in harmony with their own symphony of selves. They identify “the Single Self Assumption” as the prime reason why the benefits of having multiple selves has been ignored. This assumption holds that we each are or ought to be a single consistent self, yet we all recognize, in reality, that we are different in different situations. James Fadiman, Ph.D., did his undergraduate work at Harvard and his graduate work at Stanford, doing research with the Harvard Group, the West Coast Research Group in Menlo Park, and Ken Kesey. A former president of the Institute of Noetic Sciences and a professor of psychology, he taught at the Institute of Transpersonal Psychology, now Sofia University, which he helped found in 1975. An international conference presenter, workshop leader, management consultant, and author of several books and textbooks, he lives in Menlo Park, California, with his filmmaker wife, Dorothy. Jordan Gruber, J.D., Practical Wordsmith and Renaissance Writer, collaborative writer, ghost writer, editor, and coach, has forged and sculpted authoritative volumes in forensic law, financial services, psychology, and health and wellness. A graduate of Binghamton University and the University of Virginia School of Law, he founded the Enlightenment.Com website and is now a leading advocate of rebound exercise through his co-authored book, The Bounce. He lives in Menlo Park, California, with his wife and family. Learn more about Simran here: www.iamsimran.com www.1111mag.com/

Why you are a different you at different times and how that's both normal and healthy... Each of us is comprised of distinct, autonomous, and inherently valuable “selves”. They also show that honoring each of these selves is a key to improved ways of living, loving, and working. Instead of seeing the existence of many selves as a flaw or pathology, Gruber and Fadiman reveal that the healthiest people, mentally and emotionally, are those that have naturally learned to appreciate and work in harmony with their own symphony of selves. They identify “the Single Self Assumption” as the prime reason why the benefits of having multiple selves has been ignored. This assumption holds that we each are or ought to be a single consistent self, yet we all recognize, in reality, that we are different in different situations.

Why you are a different you at different times and how that's both normal and healthy... Each of us is comprised of distinct, autonomous, and inherently valuable “selves”. They also show that honoring each of these selves is a key to improved ways of living, loving, and working. Instead of seeing the existence of many selves as a flaw or pathology, Gruber and Fadiman reveal that the healthiest people, mentally and emotionally, are those that have naturally learned to appreciate and work in harmony with their own symphony of selves. They identify “the Single Self Assumption” as the prime reason why the benefits of having multiple selves has been ignored. This assumption holds that we each are or ought to be a single consistent self, yet we all recognize, in reality, that we are different in different situations.

On today's episode, Oteil and Mike welcome Dr. James Fadiman, psychologist and writer known for his extensive work in the area of psychedelic research. Dr. Fadiman shares his first life-changing experiences with psychedelics, talks about using psychedelics as compared to prescription drugs, the personalities of the best spiritual teachers, and more. He also talks about his research in microdosing, what he's seen, and what he's learned. If you're interested in learning about the potential benefits of psilocybin and other psychedelics, this is a must-listen episode. *DISCLAIMER: This podcast does NOT provide medical advice. The information contained in this podcast is for informational and entertainment purposes only. No material in this podcast is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen* Dr. James Fadiman, PhD is often referred to as the initiator of scientific research on microdosing. Dr. Fadiman did his undergraduate work at Harvard and his graduate work at Stanford, doing research with the Harvard Group, the West Coast Research Group in Menlo Park, and Ken Kesey. He is the author of The Psychedelic Explorer's Guide. Called “America's wisest and most respected authority on psychedelics and their use,” Jim Fadiman has been involved with psychedelic research since the 1960s. Since 2010, he has been collecting reports from thousands of people who experimented with microdosing following a schedule (his suggested one day on, two days off protocol is now known as the Fadiman protocol). Many of them shared how they overcame their insecurities, anxiety, depression and stress, but also migraines, cluster headaches and menstrual complaints. Seven years later, Dr. Fadiman is convinced that microdosing can have enormous medical benefits, and hardly any risks.  This podcast is available on Apple Podcasts, Spotify, or wherever you get your podcasts. Please leave us a rating or review on iTunes! Comes A Time is brought to you by Osiris Media. Hosted and Produced by Oteil Burbridge and Mike Finoia. Executive Producers are Christina Collins and RJ Bee. Production, Editing and Mixing by Eric Limarenko and Matt Dwyer. Theme music by Oteil Burbridge. To discover more podcasts that connect you more deeply to the music you love, check out osirispod.com ------- Visit SunsetlakeCBD.com and use the promo code TIME for 20% off premium CBD products Start your path toward investments that align with your values. Visit www.greenfuturewealth.com and mention "Osiris" when scheduling your free virtual consultation to receive your free investment report. Hosted on Acast. See acast.com/privacy for more information. Learn more about your ad choices. Visit megaphone.fm/adchoices

On today’s episode, Oteil and Mike welcome Dr. James Fadiman, psychologist and writer known for his extensive work in the area of psychedelic research. Dr. Fadiman shares his first life-changing experiences with psychedelics, talks about using psychedelics as compared to prescription drugs, the personalities of the best spiritual teachers, and more. He also talks about his research in microdosing, what he’s seen, and what he’s learned. If you’re interested in learning about the potential benefits of psilocybin and other psychedelics, this is a must-listen episode.*DISCLAIMER: This podcast does NOT provide medical advice. The information contained in this podcast is for informational and entertainment purposes only. No material in this podcast is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen*Dr. James Fadiman, PhD is often referred to as the initiator of scientific research on microdosing. Dr. Fadiman did his undergraduate work at Harvard and his graduate work at Stanford, doing research with the Harvard Group, the West Coast Research Group in Menlo Park, and Ken Kesey. He is the author of The Psychedelic Explorer’s Guide. Called “America’s wisest and most respected authority on psychedelics and their use,” Jim Fadiman has been involved with psychedelic research since the 1960s.Since 2010, he has been collecting reports from thousands of people who experimented with microdosing following a schedule (his suggested one day on, two days off protocol is now known as the Fadiman protocol). Many of them shared how they overcame their insecurities, anxiety, depression and stress, but also migraines, cluster headaches and menstrual complaints. Seven years later, Dr. Fadiman is convinced that microdosing can have enormous medical benefits, and hardly any risks. This podcast is available on Apple Podcasts, Spotify, or wherever you get your podcasts. Please leave us a rating or review on iTunes!Comes A Time is brought to you by Osiris Media. Hosted and Produced by Oteil Burbridge and Mike Finoia. Executive Producers are Christina Collins and RJ Bee. Production, Editing and Mixing by Eric Limarenko and Matt Dwyer. Theme music by Oteil Burbridge. To discover more podcasts that connect you more deeply to the music you love, check out osirispod.com-------Visit SunsetlakeCBD.com and use the promo code TIME for 20% off premium CBD productsStart your path toward investments that align with your values. Visit www.greenfuturewealth.com and mention "Osiris" when scheduling your free virtual consultation to receive your free investment report. See acast.com/privacy for privacy and opt-out information.

On today’s episode, Oteil and Mike welcome Dr. James Fadiman, psychologist and writer known for his extensive work in the area of psychedelic research. Dr. Fadiman shares his first life-changing experiences with psychedelics, talks about using psychedelics as compared to prescription drugs, the personalities of the best spiritual teachers, and more. He also talks about his research in microdosing, what he’s seen, and what he’s learned. If you’re interested in learning about the potential benefits of psilocybin and other psychedelics, this is a must-listen episode.*DISCLAIMER: This podcast does NOT provide medical advice. The information contained in this podcast is for informational and entertainment purposes only. No material in this podcast is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen*Dr. James Fadiman, PhD is often referred to as the initiator of scientific research on microdosing. Dr. Fadiman did his undergraduate work at Harvard and his graduate work at Stanford, doing research with the Harvard Group, the West Coast Research Group in Menlo Park, and Ken Kesey. He is the author of The Psychedelic Explorer’s Guide. Called “America’s wisest and most respected authority on psychedelics and their use,” Jim Fadiman has been involved with psychedelic research since the 1960s.Since 2010, he has been collecting reports from thousands of people who experimented with microdosing following a schedule (his suggested one day on, two days off protocol is now known as the Fadiman protocol). Many of them shared how they overcame their insecurities, anxiety, depression and stress, but also migraines, cluster headaches and menstrual complaints. Seven years later, Dr. Fadiman is convinced that microdosing can have enormous medical benefits, and hardly any risks. This podcast is available on Apple Podcasts, Spotify, or wherever you get your podcasts. Please leave us a rating or review on iTunes!Comes A Time is brought to you by Osiris Media. Hosted and Produced by Oteil Burbridge and Mike Finoia. Executive Producers are Christina Collins and RJ Bee. Production, Editing and Mixing by Eric Limarenko and Matt Dwyer. Theme music by Oteil Burbridge. To discover more podcasts that connect you more deeply to the music you love, check out osirispod.com-------Visit SunsetlakeCBD.com and use the promo code TIME for 20% off premium CBD productsStart your path toward investments that align with your values. Visit www.greenfuturewealth.com and mention "Osiris" when scheduling your free virtual consultation to receive your free investment report. See acast.com/privacy for privacy and opt-out information.

In this episode of the Plant Medicine Podcast, Dr. James Fadiman and Adam Bramlage join to discuss the finer points of microdosing and their upcoming Microdosing Movement course. Dr. Fadiman is a world-renowned psychedelic researcher and transpersonal psychologist who has made seminal contributions to the contemporary understanding of microdosing coach with clients from a wide range of backgrounds to help craft individualized protocols to best harness the potentials of microdosing. Together with the San Francisco Psychedelic Society and Jakobien & Hein of The Microdosing Institute, they will be leading the upcoming six-week Microdosing Movement course.  In this discussion, Dr. Fadiman and Adam touch on many nuanced topics relating to microdosing, ranging from individualized protocols to current research. Dr. Fadiman tells of his experience gathering information on microdosing through his own study and how this originated what became known as the Fadiman protocol for microdosing. Dr. Fadiman also discusses some conclusions that can be drawn from experience reports, such as the efficacy of microdosing for combatting conditions such as addiction or depression.  Additionally, Adam shares the details of the Microdosing Movement course, emphasizing how building community is foregrounded in the course design. In addition to lectures by experts like Dr. Fadiman, participants will have the opportunity to socialize with other students, integrate the content, and ask questions at weekly communiTEA gatherings over Zoom. The microdosing movement course runs from Sunday, December 13th through Tuesday, January 19th. Additional information and registration linked below: Dr. Fadiman can be reached at jfadiman@gmail.com. In this episode: How Dr. Fadiman developed his microdosing protocol What we know about tolerance when it comes to psychedelics Recent research findings suggesting microdosing could also be effective in treating pain Details of the upcoming microdosing movement course How community enriches microdosing outcomes Quotes "The most important thing to get across is that each person is an individual and no one protocol is going to work for everybody. Everybody has different needs." [12:42] "And particularly people are saying, not that meditation improves your microdosing, but that microdosing absolutely improves your meditation." [15:36] "We're just seeing extremely positive results across the board, and we're seeing that the longer people microdose, the less often they need to microdose." [41:40] "There's so many different applications for this, with so many different conditions, and each day I get new emails or new contracts from people who are using it for totally new things." [43:54] Links The Microdosing Movement Course Microdosing Psychedelics Website Dr. Fadiman's Website Psychedelic Medicine Association Porangui

James Fadiman is known as the author of The Psychedelic Explorer’s Guide and as one of America's most well-known proponents of microdosing. While a Harvard undergrad, he was the "teacher's pet" of Ram Dass, then known as Richard Alpert; as a graduate student at Stanford University, he became a research assistant at Myron Stolaroff's famed International Foundation for Advanced Study, an early non-profit situated in Menlo Park that guided the uninitatited into the psychedelic experience and studied the outcomes. Fadiman was also one of the first teachers at the Esalen Institute, beginning in the fall of 1962 with the workshop "The Expanding Vision," co-taught with Willis Harman. He has continued a lifelong association with Esalen and with psychedelics, and has appeared in countless films as an authority on such matters, including 2013’s "Science and Sacraments" and 2009’s "Inside LSD." Other books authored by Fadiman include Be Love Now, Essential Sufism, and The Other Side of Haight. Together we explored microdosing, the mystical experience, the Human Potential Movement, his friendship with the Merry Pranksters, and more.

James Fadiman is an American psychologist and writer. He is acknowledged for his extensive work in the field of psychedelic research. He co-founded along with Robert Frager the Institute of Transpersonal Psychology, which later became Sofia University, where he was a lecturer in psychedelic studies. He is one of the foremost researchers in microdosing. Dr. Fadiman recently released "Your Synchrony of Selves," positing the theory of a healthy multiplicity of selves.https://www.jamesfadiman.com

James Fadiman, PhD, was a part of the first wave of pioneering psychedelic researchers in the 1960s in the US. He’s the co-founder of the Institute of Transpersonal Psychology, now known as Sofia University, and he’s the author of several well-known psychedelics books, including The Psychedelic Explorer’s Guide. From his initial rediscovery of microdosing and developing a protocol based on early reports, Dr. Fadiman teamed up with Dr. Sophia Korb to record and pattern-map the microdosing experiences of several thousand individuals from 51 countries. In this episode, Dr. Fadiman answers listener-submitted questions regarding microdosing psilocybin and LSD. He discussed dosing recommendations, tolerance, microdosing's general effects on healthy normals, and its specific effects on a number of conditions, ranging from depression to PMS. He also covered a variety of additional areas where people benefit from microdosing, including academic performance and athletics.  In the last part of the episode, Dr. Fadiman discusses his new book, Your Symphony of Selves. He points out that we have not one, but a multitude of selves, and that we can learn to shift between them consciously. Further following this idea, he illustrates how we can save a lot of mental distress by not over-identifying with any particular one of our selves, and how we can extend that concept to those around us. This helps us not only forgive others when one of their selves may have acted in a displeasing way but also helps us forgive and go easy on ourselves when we act in a way that we later find distressing or shameful.   In this episode: The reported benefits and risks of microdosing psilocybin mushrooms and LSD. Whether someone’s height and weight makes a difference on their dosage. The overwhelming number of those suffering from depression who reported significant improvements in their survey. Why microdosing may not be advisable for those with anxiety. Dr. Fadminan reports on study findings regarding conditions including depression, PMS, migraine headaches, and bipolar    Quotes: “A lot of people have found that when they’re tapering off of an SSRI, which means taking it down very, very slowly over a period of maybe a couple of months from full dose to zero, that microdosing helps. That makes it easier. Makes it maybe even a little faster.” [14:13] “I’m an enthusiast for the effect of microdosing, but I never recommend that anyone microdose. That’s a personal decision based on information, but the nice thing is the risk/reward ratio, which is how dangerous versus how beneficial. It’s very good for microdosing. Meaning, if you take it, it’s very low risk, and yeah, from the reports, we have a lot of possibility of benefits.” [35:00] “What we’ve found is that about 80% of the people who come in with heavy depression, and again, most of them having failed medications or other therapies, we’ve about an 80% turnaround rate where they’re not depressed. That’s really striking.” [42:00] “They (students) say: “Microdosing is very much like Adderall, except with none of the very disturbing side effects.” Adderall includes crashing, by the way. And addiction.” [49:18] “Individual neurons in the laboratory, exposed to microdoses, grow into more healthy, more complex neurons with more dendrites, meaning more communication capacity.” [52:17] In discussing his new book, Your Symphony of Selves: “The inconsistencies you see in yourself and particularly in the people you love are not inconsistencies. It is that they have several selves, and you do too. And if you begin to think in that way, curiously, the world becomes easier. You understand things differently and you are kinder to yourself and more compassionate to others.” [1:10:43]   Links: Psychedelic Medicine AssociationMicrodosing Psychedelics  James Fadiman’s website and email: jfadiman@gmail.com Cluster Busters - treatment for cluster headaches Get 20% off everything at Octagon Biolabs with coupon code 'plantmedicine' Porangui Studies mentioned:Psychedelics Promote Structural and Functional Neural Plasticity Books Mentioned: A Really Good Day by Ayelet Waldman The Psychedelic Explorer’s Guide by James Fadiman PhD Your Symphony of Selves by James Fadiman PhD, Jordan Gruber JD

Micro-dosing, taking small doses of psychedelic substances, like LSD or psilocybin-containing “magic” mushrooms, probably entered the public consciousness in early 2015, after James Fadiman, PhD and author of The Psychedelic Explorer's Guide, appeared on the Tim Ferris Podcast. Fadiman is the author of the 2011 book “The Psychdelics Explorer's Guide” where can be credited with presenting the idea of taking a “sub-perceptual” dose of a hallucinogen, like LSD or Psilocybe cubensis “magic” mushrooms, that contain the hallucinogen psilocybin. A sub-perceptual dose means that, while these substances still exert effects, they don't produce a noticeable hallucinogenic “high”. While other substances can be used, the most common way to practice micro-dosing is with about 1/10th to 1/20th of a standard “trip dose” of LSD or psilocybin, the two most commonly taken psychedelics. In this episode I talk to Dr. Amanda Satov, a fellow naturopathic doctor. Amanda became interested in the healing power of psychedelic plant medicines on a trip to the Amazon rainforest of Peru. Her background in culinary arts and her interest in working with patients through transitional periods in their lives, led to her deep dive in the history, science and current research surrounding psychedelic, or entheogenic medicines. Dr. Amanda is also a reiki practitioner. She is a fellow Toronto practitioner. You can find Dr. Amanda Satov, ND at: https://www.amandasatov.com/ and on Instagram: https://www.instagram.com/amandasatov.nd/ Now, the psychedelic medicines, like psilocybin or LSD, that we talk about in this episode are not currently approved for therapeutic use. Nor are they legal to procure outside of certain exceptions for scientific research. Dr. Amanda and I are having this discussion because we're interested in it and excited about what the future holds for using psychedelics in the realm of mental health, however we are in no way advocating their use outside of a therapeutic encounter. This discussion is for educational purposes only. To learn more: https://remedycentre.ca/ https://www.fieldtriphealth.com/ https://thethirdwave.co/ https://maps.org/ https://clearskyibogaine.com/ibogaine-toronto/ Good Mood Foundations: a 6-week lifestyle program for mental health and emotional wellness: taliand.com/good-mood-learn

FAKE NEWS. That's what this podcast is. I talk about comedy in an aborted fashion. I make suggestions for microdosing that is mostly accurate. NOTE: Lysergi.com is closed. I can't vouch for Chem Theory, but I'll check them out one day and let you know. But the Fadiman, crypto stuff is still legit. 5mcg of ALD-52 following the Fadiman protocol has done me good, but you may have side effects like interdimensional travel. Please subscribe- Apple- https://apple.co/2CMR4IA Stitcher- http://bit.ly/2uBCwXT YouTube- http://bit.ly/2FPk44h Follow me! Instagram- http://bit.ly/2Ud9InN Twitter- http://bit.ly/2JUGEg1

A new type of question and answer game in which the public quiz the professionals. The public are invited to send in questions with their answers and if they are used on the show the sender gets $2. Further more if the professionals get them wrong the sender gets a further $5. The show was created and run by Dan Golenpaul whose idea was to reverse the typical type of quiz show by allowing an intelligent, educated public ask the questions and put the alleged authorities on the spot. He certainly got the mix right by employing Clifton Fadiman as moderator of a panel of four experts, which would always include 2 or 3 regulars and guest personalities. Fadiman himself came from a background in books being a book critic for the New Yorker. Other regulars included Science writer Bernard Jaffe, professor of philosophy Dr Harry Overstreet, Marcus Duffield of the New York Herald-Tribune and later John Kieran a sport's columnist for the New York Times and Oscar Levant a pianist and composer. What all of these had in common was their broad interests and knowledge and quick and slicing wit. The intellectual questions were a catalyst for talk and the hilarious humor that emerged. "An uproarious error or a brilliant bit of irreverence was rated far above any dull deliverance of the truth," wrote John Kieran, one of the four major personalities. Go ahead and sample any of these shows and I guarantee you won't be disappointed. Broadcast Date: January 3, 1944 --- Send in a voice message: https://anchor.fm/dennis-moore9/message Support this podcast: https://anchor.fm/dennis-moore9/support

Maria Fadiman – Coming Out On The Other Side of Your Autoimmune ReactionsAired Friday, 19 April 2019, 7:00 PM ETIn this fascinating, raw, and real chat, we explore the absurdity of ‘all-of-this' along with what to do with the all too common statement “It's all in your head” with mycotoxins autoimmune thriver, National Geographic explorer and FAU professor, Maria Fadiman.Maria Fadiman works to make a difference in the world (really, the whole world) and embraces the challenges that come with the explorer kind of life. She is the creator of a compelling and funny one-woman show about discovering her autoimmune disorder, dealing with it, and getting back to being a “badass international explorer” even with an autoimmune condition. Just some of what she shares with us is:• The freedom when you discover ‘It's a crazy reaction, AND I'm not crazy…' • How to find the humor and uncover happiness within your diagnosis, • Why it is essential to have someone who “helps you think it out…” • The mindset tips that keep this international explorer continuing her adventures, plus so much more.Our guest Maria Fadiman is an associate professor in the Geosciences at Florida Atlantic University and a National Geographic Emerging Explorer. She researches the human/environmental aspect of conservation, focusing on ethnobotany, the study of the relationship between people and plants, and has given two TEDx talks. In addition to her academic publications, she writes adventure essays and is one of the invited contributors to the book, Global Chorus, along with others such as the Dalai Lama and Jane Goodall.Listen to this revealing episode first, Friday, April 19th at 7 PM ET at www.UnderstandingAutoimmune.com/Maria and later in podcast and video.

Throughout my twenties I harboured a strong desire to read the Great Books, but it wasn't until I'd finished university and come across Clifton Fadiman's Lifetime Reading Plan at the now defunct Book Den in Ottawa on MacLaren street, that I started to act seriously on the urge. It, and the 100 books recommended, had and continue to have a profound impact on my life. So, I was thrilled to learn that Anne Fadiman had written a memoir about her father called The Wine Lover's Daughter.   Anne is an essayist and reporter. The Spirit Catches You and You Fall Down, her account of the cross-cultural conflicts between a Hmong family and the American medical system, won a National Book Critics Circle Award. Ex Libris: Confessions of a Common Reader, is a book about books (buying them, writing in their margins, and arguing with her husband on how to shelve them). At Large and At Small is a collection of essays on Coleridge, postal history, and ice cream, among other topics; it was the source of an encrypted quotation in the New York Times Sunday Acrostic. I met with Anne at the Brattleboro Literary Festival to talk, among other things, about opening sentences, erotic relationships with wine, male chauvinism, wine libraries, 900 bottles of wine, childhood poverty, Columbia University, leaving parents behind, Jewishness, Irving Wallace, cut roots, John Erskine, Great Books, The Lifetime Reading Plan and life lessons, prisoners, oaklings, Information Please, Harpo Marx, a patrician mid-Atlantic accent, translating Neitsche, retrieving wives, lovers that don't disappoint, Simon and Schuster, The New Yorker, multi-tasking, self-deprecation, counterfeits, mailing home toilet paper, hatred of television, open-mindedness and The New Lifetime Reading Plan, and the ability to take hedonistic pleasure in books and wine. 

Well we've been lining this one up for a while - I'm going to share my microdosing experience with you. Firstly I think it's important to spend the first fe minutes of this podcast rationalising (or at least me trying to rationalise) the context in which I place, and have approached, microdosing. I've been microdosing psilocybyn every 4 days and i'm going to tell you about how much, when, and for how long (a cycle) I supplement for. Hear me out and let us know what you think - have you tried it? Are you thinking about it? Have you tried microdosing with another pyschedelic?  Get in touch: email community@wriinkle.com DM us on the wriinkle Instagram I also mention Dr James Fadiman & Dr Rosiland Watts - google them and have a look into their stuff - they've both appeared on Podcasts and Ted Talks and have books and papers. Dr Fadiman on Tim Ferris: https://tim.blog/2015/03/21/james-fadiman/ Dr Watts on Y Combinator: https://www.youtube.com/watch?v=qGGFjUDXvrE Hope you enjoy this one! Anton :) music by Dyalla Swain https://soundcloud.com/dyallas

Follow Chris Ryan on Instagram Follow me on Instagram Buy me a coffee on Patreon Dr. Jim Fadiman is considered America's wisest and most respected authority on psychedelics and their use. In 1974 he co-founded the Institute for Transpersonal Psychology, and has since continued to explore potential medical and creative uses of psychedelic drugs. In his most recent book, The Psychedelic Explorer's Guide: Safe, Therapeutic and Sacred Journeys (2011), he provides insight into safe and correct uses of psychedelic drugs. The book was inspired by his unique knowledge of psychedelic experiences and his desire to explain beneficial uses of those substances. He received his B.A. from Harvard University in Social Relations in 1960, and his M.A. and Ph.D from Stanford University in Psychology in 1962 and 1965, respectively.   Chris Ryan and his work have been featured just about everywhere, including: MSNBC, Fox News, CNN, NPR, The New York Times, The Times of London, Playboy, The Washington Post, Time, Newsweek, The Atlantic, Outside, El Pais, La Vanguardia, Salon, Seed, and Big Think.  A featured speaker from TED in Long Beach, CA to The Festival of Dangerous Ideas at the Sydney Opera House to the Einstein Forum in Pottsdam, Germany, Chris has consulted at various hospitals in Spain, provided expert testimony in a Canadian constitutional hearing, and appeared in well over a dozen documentary films. Even before co-authoring the New York Times best-seller, Sex at Dawn: How We Mate, Why We Stray, and What it Means for Modern Relationships (translated into 15 languages), with his partner-in-crime (and wife), Cacilda Jethá, MD, Chris was on a wild ride. After receiving a BA in English and American literature in 1984 he spent the next two decades traveling around the world, pausing in unexpected places to work at decidedly odd jobs (e.g., gutting salmon in Alaska, teaching English to prostitutes in Bangkok and self-defense to land-reform activists in Mexico, managing commercial real-estate in New York’s Diamond District, helping Spanish physicians publish their research). In his mid-30s, Chris decided to pursue doctoral studies in Psychology. Drawing upon his multi-cultural experience, Chris' research focused on distinguishing the human from the cultural, first by focusing on shamanism and ethnobotony—studying how various societies interact with altered states of consciousness and the sacred plants that provoke them—and later, by looking at similarly diverse cultural perspectives on sexuality. His doctoral dissertation was a multi-disciplinary investigation of prehistoric human sexual behavior, guided by the world-renowned psychologist, Stanley Krippner, at Saybrook Graduate School, in San Francisco, CA. Chris is finishing a new book for Simon and Schuster tentatively called Civilized to Death: Why Everything's Amazing but Nobody's Happy, due out in 2017—and he puts out a weekly podcast, called Tangentially Speaking, featuring conversations with interesting people, ranging from famous comics to bank robbers to drug smugglers to porn stars to authors to plasma physicists.

James Fadiman is a Harvard-trained psychologist and writer, who is known for his extensive work in the field of psychedelic research. He co-founded, along with Robert Frager, the Institute of Transpersonal Psychology, which later became Sofia University, where he was a lecturer in psychedelic studies. Fadiman is author of The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys. In this episode, we discuss: - Why he decided to scientifically study the positive effects of LSD - Why the psychedelic experience is so transformative for so many people - How the psychedelic experience evaporates boundaries - The limitations of science - Fadiman’s experience with Abraham Maslow on an airplane - The founding of transpersonal psychology - The potential benefits of "psychedelic therapy" - How one can have enlightenment without compassion ("false enlightenment") - The importance of the Bodhisattva Path - How accepting our multiple selves can increase understanding and compassion

Microdosing: The Phenomenon, Research Results, and Startling Surprises From Psychedelic Science 2017 Yes, Dr. Fadiman is back on the show! I know it seems disproportionate and it is. But after you listen to this episode you'll see why! Microdosing is by far one of the most popular revolutions happening within the psychedelic community today. The wide ranging applications for use in increased cognitive capacity based experiences is fast becoming a legitimate psychedelic method for use within the general population. James Fadiman and Sophia Korb at the center of cyclone with their ongoing research of over 1500 active participants.  From their site,  These are the three most frequently asked questions: How much is a microdose? Most people start at 1/20 to 1/10 of a recreational dose of whatever substance they are trying and adjust based on their experience. If you are experiencing visual effects, you have taken too much. How often are microdoses taken? Most participants dose every three days. Is microdosing right for me? Only you can make that determination. There is more information about who has benefited so far and possible risks in the full FAQ. Over 1500 participants have reported their experiences of microdosing as of this writing, and submitted narrative reports and daily data. We are taking time to read and analyze and report on all the data.  

Dr. James Fadiman is considered America's wisest and most respected authority on psychedelics and their use. In 1974 he co-founded the Institute for Transpersonal Pyschology, and has since continued to explore potential medical and creative uses of psychedelic drugs. In his most recent book, The Psychedelic Explorer's Guide: Safe, Therapeutic and Sacred Journeys (2011), he provides insight into safe and correct uses of psychedelic drugs. The book was inspired by his unique knowledge of psychedelic experiences and his desire to explain beneficial uses of those substances. He received his B.A. from Harvard University in Social Relations in 1960, and his M.A. and Ph.D from Stanford University in Psychology in 1962 and 1965, respectively.

Spoke with Dr. James Fadiman about his absolutely fascinating new findings on microdosing psychedelics. He is THE guy when it comes to this stuff. Be part of the study - microdosingpsychedelics.com More about Dr. Fadiman - jamesfadiman.com Twitter: @Jfadiman Watch Jim's talk at Psychedelic Science 2017 goo.gl/aYGzVT More about the conference and other talks available at psychedelicscience.org HUGE Thank you to MAPS.org Follow us: @SeanVeryApe @VeryApeTV Subscribe on iTunes: goo.gl/Ytp3nx Recorded 4/23/17 Oakland, CA veryape.tv

Ayelet Waldman, novelist, essayist, screenwriter, and activist, talks about her new non-fiction book A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life, in which she describes a month long experiment treating her unstable moods with minuscule doses of LSD. Finding psychotropic med prescriptions of little help, Waldman became intrigued by the work of Dr. James Fadiman, a psychologist and researcher who has chronicled the positive effects of microdosing LSD. Waldman is also a lawyer, an accomplished former federal public defender and former teacher at Boalt Hall, U. C. Berkeley's law school. Her legal career includes working to rescue women from prison and advocating for drug-policy reform.TRANSCRIPTSpeaker 1:Method to the madness is next. You're listening to method to the madness, a weekly public affairs show on k a l expertly celebrating bay area innovators. I'm your host, Lisa Kiefer, and today I'll be talking with novelist and essayist. I yell at Wildman. We'll be talking about her new book, a really good day. How microdosing made a mega difference in my mood, my marriage, and my life. Chris, your pleasure to be here. It's great. After I first [00:00:30] got lost on campus, which I will probably do till the end of time, it's on your used to teach on camera. Speaker 2:I taught here at the boat law school for seven semesters yet I want to talk about your new book. I really liked it and so glad the superficial level of it. It's a diary of you microdosing for 30 days, but yes, it's so much more than that. It's about how the war on drugs has failed drug reform policy. It's about psychedelic research. It's about your family. Yes. It's about mood disorders and how they affect family. So you're a legal professional. Yes. And you are a a federal public defender. A criminal defense [00:01:00] lawyer. Tell us the journey of how you got to a schedule one illegal drug for your mood disorder. So it was really a matter of desperation. So I have a mood disorder, but I have a mood disorder that was for many, many years, very well controlled. You know, I'm not one of those people who doesn't take our medicines. Speaker 2:I took my medicine and I took it regularly. My mood disorder was diagnosed as premenstrual dysphoric disorder and the easiest way to understand that is just pms on steroids. It took a while to get the diagnosis. I had a lot of misdiagnoses [00:01:30] first, but eventually I got the diagnosis. I was treated by a psychiatrist who had an expertise in women's mood and hormones and she put me on a very easy to follow very specific medication regimen. I took a week of antidepressants right before my period and for many years that worked great. It was life altering. I mean it was amazing there. I was one month, didn't know what to do, cycling uncontrollably the next month, popping a pill and feeling much better. But then of course I got older [00:02:00] and when you hit your forties when you're a woman, you enter into this protracted period of peri-menopause, which isn't menopause when you stop getting your period, but it's kind of like the build up to that and there's so little literature on it. Speaker 2:Yeah, I thought you'd just like some, one day you're stopped getting your period. I didn't know that. For years I would get two periods a month, three periods a month, no periods, skip a bunch, get one, skip four again, another one, you know, it was just completely unpredictable and crazy. So your mood is fluctuating madly because your hormones are fluctuating madly [00:02:30] and my specific medication regimen required me to know exactly when I was going to get my period and I didn't know anymore and that catalyze this kind of mood disaster. I became a very, very depressed, but my kind of depression is an activated depression, so it's not like I crawled into bed and went to sleep. I was still very productive, but I was very quick to anger, very irritable. I was very difficult to live with and I would get into these spirals where I would be horrible to the people in my family and then I would feel shame and depressed [00:03:00] and I ultimately became suicidal before I began the microdosing experiment, I had left the place of ideation and was more into a kind of more planning phase. Speaker 2:At one point I was standing in front of my medicine cabinet, kind of evaluating its contents to see what was the most dangerous drug in it. Spoiler alert, Tylenol. I have a lot of stuff in my medicine cabinet, but that is a dangerous drug and that's when I decided to try this crazy thing. That's illegal schedule one. I decided to try micro-dosing with LSD. Tell us how you did that. You, you met [00:03:30] James Fadiman. I reached out to James Fadiman. I use an old time researcher on psychoactive drugs. The 60 60 the sixties he, yes, he was a Stanford t and a couple of other people had a study specifically designed to evaluate the effects of LSD on creative problem solving. Fadiman and his colleagues invited these 28 engineers, architects, people in those sort of beginnings of the computer industry because this was like 1966 right? Right. Speaker 2:Yeah, right. LSD was illegal. Right? They said to these people, bring a problem. You're not, [00:04:00] we're not, we're not inviting you here to seek God. We're asking you to bring, you know, a math problem and engineering problem, a design problem, something that you've had really a hard time figuring out. Bring your intractable problem to this experience and we'll see what happens. And so these people came in and they got dosed with LSD and the researchers watch them. And what was remarkable is that many of them not only solve their problems, but went on to have these profound insights into their work. Very few of them had kind of spiritual awakenings. [00:04:30] The study was, he said to bring in to problems that you have been unable to solve for one reason or another. Exactly directed it to problem solve. It was all about sort of set and setting. Speaker 2:It was like intention, right. You know that stupid thing they say before you do your yoga. Having the intention to solve your problem actually resulted in some number of these individuals solving their problems, going on to file patents and and create in some cases, companies based on these. Then of course that research was shut down and if adamant describes it, he says that he had just dosed [00:05:00] a subject group. The LSD was about to hit and they get this letter informing them that their specific permit was going to be rescinded. And so he looks at the letter and he looks at his colleague and he says, I think we got this letter tomorrow. But you know, it was really, it's a shame that that research was shut down because I think what we're seeing now with this resurgence of interest in LSD and particularly micro-dosing, which are to define it for your audience, a microdose is a small dose, a dose that's too small to elicit [00:05:30] any perceptual effects. Speaker 2:But so sub psychedelic thing. Yeah, new tripping. But it's large enough to have metabolic effects. So in a sense we're looking for something that can act in a way that you almost don't notice. If I had slipped it into your coffee right now, you would not know that you were micro-dosing except at the end of the day after our interview, after the rest of your work, you might go home and think, Huh, that was a really good day. Okay, so, so, so I know [inaudible] yes, she's written a book by Psychedelic and spiritual journeys. I said, but that's [00:06:00] not the kind of book that I'm likely to read because I'm not a particularly psych psychedelics or spiritual personal. Great is you're not. So I'm very practical. I was raised by atheist parents whose atheism was as dogmatic as a Hasidic Jews, Judaism. I mean we were, my parents raised me to have disgust for religion and for spirituality of all kinds, which I struggle with, you know, I'm trying to overcome. Speaker 2:We all try to overcome the biases of our parents. So I'm, I'm looking on the Internet. I'm in this place of profound depression, Anhedonia. [00:06:30] And I see this talk that Jim is giving and he talks about microdosing and he says that at the end of the day, people report that they had a really good day. And I felt like I'd been hit in the head with a mallet, like a real echos all. I wanted a really one really forget really good. I just wanted a good day. I wanted a day where I didn't feel this kind of sense of despair and inability to take pleasure in my family and my husband did my [00:07:00] marriage and my surroundings and so I reached out to him and he is the most loving, generous man. I mean, look, I'm a person with daddy issues. I get that. I have a very typical, my father's much older than my mother, and you talk about this in the book. Speaker 2:I was 40 when I was born, so he was older, which in the 60s that was really old, but he was a very uninvolved father and he also had his own mood disorder, so he was, it's hard to live with a parent with a mood disorder as my children can likely attest. Dr Fadiman's generosity, his warmth is his willingness to [00:07:30] talk on the phone with me for hours about my issues, about my problems, about, you know, what I tried was really, it was an, it was a novel experience for that's what you wanted. Yeah. In a, in a way or my dad and I have known one another's mood disorders forever and we've literally never spoken about it once. So one day I'm a visiting my parents and my father comes out of this room, this kind of junk room and he hands me this stack of micro cassette tapes and he says, here, do something with these tapes of my [00:08:00] psychotherapy sessions from the 80s so I have this pile of tapes of my dad's therapy and for years I just couldn't even look at them. Speaker 2:I was just like, Ugh, you know, you want to tell me how you're feeling, just talk to me. But then eventually I actually did a whole story for this American life about these tapes cause I did eventually listen to them hoping for great profound insight and got nothing. But what you did get, it's so hilarious in the history of communism, all my dad will ever talk to you about is like the history of Zionism, the history of communism, [00:08:30] Stalin's five year plan, like seriously anything you want to know about Stalin's agrarian policy. And so I put in the tape, you know what I really wanted to hear as I love my daughter, I was expecting to hear insights into his problematic relationship with his children, his terrible marriage, all that stuff. But what I ended up getting was, let me tell you a little about Stalin's five year plan. Speaker 2:I mean, he, his therapist just sat and talked about that for hours at a time. You know, you talk about how you don't get so worked up about these very issues. You just mentioned that your father, you're more circumspect [00:09:00] during that 30 days. I certainly was during those 30 days, I had a capacity for equanimity that I had not had before. I had a resurgence in my ability to enjoy beauty, my family to feel loved, to feel connected to the world. Um, I was less irritable. I didn't less judgment, less judgmental. I didn't lash out. It was really like cognitive behavioral therapy in a pill. You know, I had been in cognitive behavioral therapy, I had been in all these treatment modalities and they just hadn't worked [00:09:30] because I couldn't make myself do them. And with the LSD I was more receptive and I was more able to do that work that was necessary to maintain my mood. Speaker 2:I also incidentally, and you know this hearkens back to Jim's work in the 60s I was more productive, way more productive. This was not hypomania. This was like sit down, get to work, focus, make interesting connections, which is again not a surprise. We know that large doses of LSD, sort of more typical [00:10:00] doses cause different parts of your brain that don't normally communicate to communicate in new ways and they want to talk about that. The default mode network. Yes. So the default mode network, I mean in the most simplistic way, this is that part that like Rut that you are in your head that tells you to react in certain ways and it's kind of that directive mode. That was the voice in my head that told me I was worthless and I was useless. I was unlovable and it was a very old, very familiar set of reactions [00:10:30] and patterns, patterns and thoughts and beliefs. Speaker 2:And you know the brain develops patterns. It's what the brain likes to do. An LSD in a large dose takes your default mode network offline. It allows new patterns to form an old patterns to be kind of exploded. I'm too afraid to do an LSD trip. I was still too afraid, but in micro doses, based on my experiment and based on all of my reading and based on the research I've done on the neurochemistry of LSD and on the anecdotal evidence of many, many, many people who have now been micro-dosing [00:11:00] is that a similar function seems to occur with regular micro-dosing. It doesn't take the default mode network offline, but it allows you to develop new thought patterns and new ways of reacting. It takes you out of those traditional unproductive reflexes. And that's the neuroplasticity that you know, neuroplasticity means, you know, the way that your brain grows and changes. Speaker 2:You want a neuroplastic brain. A neuroplastic brain is a good brain. Babies' brains, very neuroplastic old ladies [00:11:30] brands, old dudes, brands less neuroplastic. You want your brain to change and grow and to constantly be, be able to think in new ways. And so you can teach an old dog new tricks with microdosing as an old dog. Look, I always resist anything that comes off as a panacea. You know, anytime you go to like a new age therapist who says, I'm going to work on your job muscles and that's going to solve your ankle pain, your back pain, your issues with your father and your flatulence problem. I see. I always [00:12:00] feel like that's the sign of a charlatan if like one thing can solve all your problems. So I, I'm very careful about making claims about microdosing, but I do think that the way that LSD and other psychedelics work on the brain holds great promise for mental illnesses that are particularly related to patterns of thinking, which, you know, a mood disorder, depression. Speaker 2:There are studies going on now, and I'm curious where they're gonna go with Jeff sessions as I knew both, uh, UCLA, NYU [00:12:30] and Johns, John Hopkins there, I think clinical stage two, two and into three. So they did a very smart thing in those research facilities. They said, we're going to study depression and anxiety in people with fatal illnesses confronting the end of their lives. And it's still Simon, not LSL Simon, not LSD. First of all, most people don't even know what psilocybin is. It's actually the psychedelic compound in magic mushrooms. But LSD, you know, LSD. Ooh, everyone's scared of LSD. It has terrible connotations. Timothy Leary, Ken Casey, you know, summer of love, blah, [00:13:00] blah, blah. Siliciden what's that? Nobody really knows that I, I can't spell it. I mean, yes, I'm dyslexic, but seriously, I wrote a whole book about this and I cannot spell silicide, but to saved my life, it was easier to get permission to study psilocybin and is a lot easier to get permission to give a psychedelic drug or any schedule one drug to someone who's dying anyway, so the studies were designed not because there's something unique about the depression at the end of life, but rather because that was the way that permission could be granted from the FDA and DEA. Speaker 2:The results have been remarkable, really remarkable. [00:13:30] I know they're unprecedented. Michael calling radar. The New Yorker about a couple of articles can is coming out with a book. I said to Michael Dell, I wonder if it's okay that like, I'm, my book's coming out before yours. He's like, oh no, no baby. You go ahead and let's see what happens. First. Mine was constructed as this experiment and then it goes off into the research, into the law. I mean, I, I talk, I spent a lot of time talking about the law and the war on drugs and I want to talk about that. Let's talk about the, the, the racism. I mean, there's never been a war on drugs that hasn't been race based in this country. It's all, I think [00:14:00] the best way to think of the war on drugs as it is a warm people of color. Speaker 2:The very first drug law in the United States was targeted at Chinese opium dens. At that point in time. There were a lot of people using opium, but the typical opium user was a white southern woman who tippled from her laudanum bottle all day long. That's opium mixed with alcohol. People gave opium to their babies to make them sleep. You know, there are all of these medicines, patent medicines that were opium based, but the law targeted Chinese immigrants in opium dens and it was really about [00:14:30] them. It wasn't about the opium per se. If you're of, you know, a wave of immigration, it's, it's characterized as, you know, fear that they'll rape white women, but it really is just, it's financial panic as xenophobia. Marijuana got tied closely to Mexican Americans. And you can see all this rhetoric at the time in the Hearst newspapers about how marijuana crazed were raping white women. Speaker 2:Alcohol is closely correlated with sexual violence in our culture but not marijuana. So again, cocaine [00:15:00] gets tied to African American communities, not because they used cocaine more, absolutely not, but it's a way to target and link and criminalize you're, there were these myths that cocaine use made African-Americans, although of course at the time they said Negroes immune to lower caliber bullets. So somehow, you know, snorting some cocaine would make a person immune to a bullet. And so that's why police departments, at least the theory is to police departments use higher caliber guns. That became the standard. So again, and [00:15:30] again, you see the war on drug tied to criminalizing communities, communities of color. And the latest iteration of this, which began in the 60s and which I thought was ending or at least drawing to a pope full close, was this rabid began with Nixon, went through Reagan, amped up with Clinton. Speaker 2:Let's be very clear targeting of communities of color with draconian prison sentences for drug crimes. So in a world where white people [00:16:00] use drugs more than people of color, you had far more people of color being arrested and incarcerated. You know, in America you go to jail for longer for marijuana in some cases, then you go to jail for murder in Europe, I mean our drug laws are out of control and we saw this massive increase in incarceration rates as a result of people of color, but also women suddenly, you know, women have had very rarely been incarcerated. The numbers were very low because women don't commit violent crimes. There's one genetic marker that you can pretty much use to evaluate [00:16:30] the likelihood of somebody committed and violent crime. And it is the y chromosome. The population of women in prison increased dramatically because of all these drug laws in these mandatory minimum sentences. Speaker 2:And I thought we had started to understand that, you know, across party boundaries, I've, I've had conversations with Senator Orrin Hatch about the injustices of the mandatory minimum sentences and the over incarceration rate. But with the election of Donald Trump in this, most schizophrenia of elections were, on the one hand, there are a bunch [00:17:00] of states that decriminalized marijuana for recreational use. Marijuana is a schedule one drug. At the same time, we elected Donald Trump who put a as attorney general, the most retrograde, racist, malevolent, incompetent, cruel and vicious white supremacist. He says he's going to go after marijuana. Yeah, that's what he's going to do. If I were in the legal cannabis business, I would be terrified to ask you about that. We don't really know yet what you're going [00:17:30] to die or what about those clinical trials that we were just tying back? Will they be shut down? Speaker 2:I don't know. I don't know if they're flying under the radar enough. If they have DEA, you know the results that you know the subjects are white. By and large, people are much more inclined to be sympathetic when the subjects are white. I don't know. But here's, I do know the United States has imposed its drug policy on the world through a very aggressive campaign that involved pox, Americana treaties and a kind of putative moral [00:18:00] leadership. So we've dictated to south and Central America. We've dictated to Europe. So when England for example, began a very small but very, very effective heroin distribution program that cut overdose rates, cut crime, and also incidentally got people off heroin. But the United States put so much pressure on the British government that they shut that program down. All the people that participate in that program, most of them went on to die. Speaker 2:So we've managed to impose our draconian prohibitionist view of drugs on the world. But the only benefit that I can see [00:18:30] to having a Cheeto, dusted mad man is our president, is that we have no moral authority. We have no claim to moral authority. Portugal, which decriminalized drugs is not going to pay any attention to a Donald Trump said the American war on drugs has destroyed Latin America. In rich, the cartels, Columbia for a long time was a country that was simply controlled by more in cartels and people lived in this kind of state of incarceration and terror [00:19:00] and this was all caused by the United States war on drugs and now countries have started to reject it. And I think that that is the one benefit of having this America first platform is that the rest of the world can go on and do good cause we haven't used our moral authority very well. Speaker 2:We spend so much money on this war on drugs like up to a trillion now or something. This lunatic for what drugs are cheaper and easier to get, which tells you that they're coming into the country more often. You're not winning a war if drugs are easier to get. You know, LSD is a non-addictive [00:19:30] drug in the entire history of LSD usage. There are two cases, human fatalities that have been attributed to LSD and those are actually suspect. So basically there's no fatal dose of Ellis, no addiction, no addiction. But you know what's more dangerous right now is that we have a situation where we have an opioid crisis in this country. Many of the states that voted so vigorously in favor of Donald Trump are littered with bodies of people dying from opioid addiction, and that is a direct result of the failed war on drugs. Speaker 2:If [00:20:00] you want to treat people and save people's lives, you have to have a harm reduction approach to drug addiction. Not at not a prohibitionist approach. You have to get in there and provide services and help and safe injection sites and safe drugs. This is typically what happens. Someone gets a prescription for O for Oxycontin, for say back pain for which it is not useful. They take it, they take it, they take it, they get addicted. Then their doctor says, well you can have any of oxycontin anymore cause you're an addict. And then they don't have any oxycontin. [00:20:30] So they go out on the street and maybe first they try to buy some pills and they get some and, but eventually pills are hard to find. They're harder to buy. They're more expensive, you know, it's cheap heroin deep, you know, it's fast, heroin's fast, then their heroin addict, and then they're criminalized. Speaker 2:Then they're criminalized. Then they're in the underground market. Then there's no FDA checking the quality of their drugs, and now heroin is quite often cut with much stronger fentanyl, hundreds of times stronger, and people are overdosing because they take an amount of drugs that they, [00:21:00] they think is a heroin, but it actually turns out to be fentanyl. It is a white epidemic in many ways. There are many, many white victims. Certainly the vast majority, maybe Jeff sessions will be willing to listen to some reason. Although again, this is a man who said that no good person has ever smoked pot. This is a man who made a quote unquote joke about the KKK, which he said he was until they, he found out I had smoked. He went there. He was fine with them until he found out they smoked pot. I wanted to ask you about how you approach drugs in your family, but you used the term harm reduction. Speaker 2:Yes. Yeah. [00:21:30] So we have, that may be the most radical thing in my book, not the taking of the LSD. I have four kids who range in age from 13 to 22 so these are our rules. We don't lie to our children about drugs ever. And they know we never lie to them. We don't allow others to lie to them. So when they are given misinformation in school programs, school programs on dare, which for many, many years taught all of this ridiculous and misinformation, it's now been improved. But you know, it basically said to kids, you know, marijuana will kill you. And then a kid will hear that message and [00:22:00] then think of their cousin who's a freshman at Yale and an ace student and a wake and bake smoker. And then they reject the whole message of dare. But anyway, they're better now. But like we educate our kids, we inundate them with information and then we have some very specific rules when it comes to pop. Speaker 2:For example, we talk a lot about the effects of marijuana on the adolescent brain. I think there's compelling evidence that the, that that that is not great that it, it does cause damage to developing brains in particular. But we are realistic. They live in Berkeley. There's no way they're going to wait till [00:22:30] their frontal lobe is fully formed before they smoke pot. So after much negotiation, we reached the agreement that nobody could smoke pot. So there were 15 only on the weekends. And if your grades drop at all, you are not only grounded but I will drug test you and you get your drug tests from Amazon, right? Yes. I can test my kids urine. I buy your intestines. I tested my LSD from a kit that I bought on Amazon. Basically I have a supply cabinet in my house that's full of MTMA testing kits. Speaker 2:Cause MTMA is the drug that I'm most concerned [00:23:00] with right now. It, it causes your body to overheat and if you have heart issues or high blood pressure, it's, you shouldn't be taking it. Basically the stupidest place to do it is like in the desert while dancing. Yes. Or at a rate where there's some thousands of people and you don't want your body temperature to be raised. And it also does this peculiar thing. It makes me more susceptible to water toxicity. What people are selling is MTMA isn't, most of the time kids will buy drugs and they'll think they're buying Molly. And it turns out that they're buying something much more toxic. So my daughter's a student at Wesleyan University and [00:23:30] half, 11 kids, I think ended up in the Er having taken something they thought was m DMA that turned out to be a synthetic called Ab Fubu, NACA Spice or k two. Speaker 2:And it was very toxic. And one of them had to be intubated and defibrillated before he, um, and he, he survived thankfully. So I keep testing kids in my cabinet and I say to my kids, those are there, if you ever are inclined to take a pill and put it in your body, first you have to test it to make sure that what you're taking is what you think you're taking because it is not safe to [00:24:00] just, and this has been a success in your household. Yes, and and in fact there have been instances where pills were people, not my own children, but others have taken a testing kit and then reported to me that it was not in fact what they thought it was threw it away. I count that as a life save. If your kid ever overdoses on heroin year, will you want your kid to be around my kid? Speaker 2:Because if your kids around a kid who has him had this kind of harm reduction education, what they're probably going to do is throw them in the bath tub with some cold water, maybe dump them in the parking lot of [00:24:30] an er and they're going to overdose and die. My kids, they know exactly what to do. They make two phone calls, they call nine one one and they say, comment with Narcan. Now we have a heroin overdose and that can cure an overdose instantaneously and they call mommy and mommy comes and deals with the legal consequences. Your last book, love and treasure was about the Holocaust. There is a character in your memoir about your microdosing Laszlo, who I think you met when you were working on love and treasure. Yes, that's such a beautiful [00:25:00] story. So allowing lowered design, his real name is a holocaust survivor, a Hungarian holocaust survivor who became very wealthy in America. Speaker 2:Very problematic relationships, difficult relationships. I'm very depressed and he went on a an Iowaska journey until I met Lazo. I, I never understood the appeal of Iowasca, but Laszlo had this incredible experience. He went to Latin America, I don't know where he's okay, but he had a guide and they had a guide and it was all very safe. So [00:25:30] his father died in the Holocaust. He and his mother survived and he had always felt this sense of, of shame and guilt for having survived. And in a way was angry the way his child was angry at his father for not having said because saying goodbye to him and had felt, even though he knew his way, he wasn't abandoned, that his father was murdered by the Arrow cross in the Hungarian fascists. He still felt the sense of, you know, a child's feeling of abandonment. Speaker 2:And he spoke to his father and he had this incredible spiritual experience that resolve that [00:26:00] pain for him. To this day I became obsessed with this idea of like, did you really speak to your father or is it saw in your head? I mean, and when I was talking to researchers about this, they would always say to me, why is that the question you're asking? I mean, isn't the interesting question that this experience resolved his pain and yet you're obsessed with whether it was real or not, and what do you even mean by real? And that's when you know, it's like, look at the results instead. I have high hopes. I think micro-dosing is kind of, it's like training wheels, right? [00:26:30] I mean microdosing for those of us who are not interested in tripping, we're talking about using a medication, the way people use antianxiety medications, but it's a medication that's actually much safer. Speaker 2:Say yes and less addictive my, but it's not an option. And that's the sad thing, right? And my message for this book is we need decriminalization. And we need research. And first the research, let's do the microdose study at the University of South Carolina. Mike met Hoffer's doing research on MTMA and PTSD with patients who have treatment resistant PTSD [00:27:00] and he has had astonishing results, which makes sense, right? MTMA is a drug that works on memory. It disconnects traumatic memories from the trauma so that you can explore the memory without the the traumatic feelings associated with it. And instead from a place of love and support, empathy, empathy, the MTMA research has the tentative preliminary support of the VA because they know that soldiers are committing suicide at astronomical rates and they have to do something. So my hope [00:27:30] is that the Pentagon and the VA will look at this research and say, we can't afford not to continue this. Speaker 2:You know, my husband and I have used MTMA at the suggestion of Sasha and an Shogun to Sasha was, it was a chemist, a local Berkeley chemist who was famous for bio as saying different drugs or synthesizing drugs and then taking them on him to himself to sort of assess their facts. And though he wasn't the first person to synthesize MTMA that honor goes to Merck. He was one of the first people to try it on himself. [00:28:00] But, um, my husband and I have used MGMA as a marital therapy tool, which is what we would, and it was initially used as, as a therapeutic tool and it's very profound and very effective and it allows us to sort of discuss the problems of our, in our relationship in a supportive and loving way. So I've been doing a lot events around the country and at every event there are a bunch of people come up and tell me they're microdosing and they say it loud and they say it proud and they're not ashamed and they're micro-dosing with LSD or psilocybin. Speaker 2:And that's great. And then there are a bunch of people who come up to me and they asked to speak to me privately [00:28:30] and they confess with great shame and embarrassment that they have a mental illness. And the idea that in our society, you don't need to be ashamed about using illegal drugs, but you need to be ashamed about being mentally ill. That's heartbreaking. And that's something we need to change. So that's one of the things that I as a person with a mental illness feel like it is my job to be public because this is not something to be ashamed of and I won't allow others to experience that shame. [00:29:00] Okay. Running out of time and I wanted to ask you, what is next on your plate? The Vallejo novel to my publisher, I'm working on a TV show that it's based on a true story but it's an it's narrative. Speaker 2:It's not documentary and it's basically about why we don't believe women who have been raped even when they do everything right and I'm working on another TV show about the first women combat soldiers in a legal combat soldiers in United States military history team, lioness in the Iraq war and because I feel like now for the next [00:29:30] four to eight to forever years, the work that I do has to have meaning and it has to have greater purpose and I'm trying to figure out what that means for me right now. If somebody has a about your book, they can go to our website, which is ILR, waldmann.com and there's lots of resources there. There's lots of articles about the research, and I have lots of resources for people with mental health issues, and I have lots of articles about the drug war, all sorts of things. Twitter, Facebook, email, and I'm easy to reach. [00:30:00] That was, I yell at Waldmann, novelist, SAS, former federal public defender and criminal defense lawyer. We'd been talking about her new book, a really good day. How microdosing made a mega difference in my mood, my marriage, and my life. You've been listening to method to the madness. We'll be back next Friday. Speaker 3:Yeah. See acast.com/privacy for privacy and opt-out information.

Duffys Tavern Guest Clifton Fadiman 6-15-43 http://oldtimeradiodvd.com 625

DISCLAIMER: DO NOT CONSUME ANY DRUGS WITHOUT CONSULTING A MEDICAL PROFESSIONAL. THIS IS FOR INFORMATIONAL PURPOSES ONLY.JAMES FADIMAN, Ph.D., did his undergraduate work at Harvard and his graduate work at Stanford, doing research with the Harvard Group, the West Coast Research Group in Menlo Park, and Ken Kesey. He is the author of The Psychedelic Explorer's Guide.Called “America’s wisest and most respected authority on psychedelics and their use,” Jim Fadiman has been involved with psychedelic research since the 1960s. In this episode, we discuss the immediate and long-term effects of psychedelics when used for spiritual purposes (high dose), therapeutic purposes (moderate dose), and problem-solving purposes (low dose). Fadiman outlines best practices for safe "entheogenic" voyages learned through his more than 40 years of experience--from the benefits of having a sensitive guide during a session (and how to be one) to the importance of the setting and pre-session intention. And that's just the tip of the iceberg.We also discuss new uses for LSD and other psychedelics, including extremely low doses for improved cognitive function. Cautioning that psychedelics are not for everyone, he dispels the myths and misperceptions about psychedelics, which are commonly circulated in textbooks. Fadiman explain how -- in his opinion -- psychedelics, used properly, can lead not only to healing but also to scientific breakthroughs and spiritual epiphanies.Show notes and links for this episode can be found at www.fourhourworkweek.com/podcast***If you enjoy the podcast, would you please consider leaving a short review on Apple Podcasts/iTunes? It takes less than 60 seconds, and it really makes a difference in helping to convince hard-to-get guests. I also love reading the reviews!For show notes and past guests, please visit tim.blog/podcast.Sign up for Tim’s email newsletter (“5-Bullet Friday”) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Interested in sponsoring the podcast? Visit tim.blog/sponsor and fill out the form.Discover Tim’s books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissFacebook: facebook.com/timferriss YouTube: youtube.com/timferriss

Fadiman on LSD: Setting by Dr. Richard L. Miller

Fadiman on LSD: Set & Setting by Dr. Richard L. Miller

Fadiman on LSD: Creativity & Stigma by Dr. Richard L. Miller

Fadiman on LSD: User Experience & Dose by Dr. Richard L. Miller

Fadiman on LSD: Pharmacology by Dr. Richard L. Miller

Fadiman on LSD: Safety by Dr. Richard L. Miller